[S02DA03, antipyrine, The metabolism of Cyclophosphamide can be decreased when combined with Antipyrine.]
[G03XB02, ulipristal, The metabolism of Ulipristal can be increased when combined with Cyclophosphamide.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Cyclophosphamide.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cyclophosphamide.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Cyclophosphamide.]
[L04AA27, fingolimod, Cyclophosphamide may increase the immunosuppressive activities of Fingolimod.]
[M03AB01, succinylcholine, The serum concentration of Succinylcholine can be increased when it is combined with Cyclophosphamide.]
[J01EC02, sulfadiazine, The metabolism of Cyclophosphamide can be decreased when combined with Sulfadiazine.]
[S01AB01, sulfamethizole, The metabolism of Cyclophosphamide can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Cyclophosphamide.]
[J01EC03, sulfamoxole, The metabolism of Cyclophosphamide can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The metabolism of Cyclophosphamide can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Cyclophosphamide can be increased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The metabolism of Cyclophosphamide can be decreased when combined with Sulfisoxazole.]
[N05AL01, sulpiride, Sulpiride may increase the neurotoxic activities of Cyclophosphamide.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be decreased when combined with Cyclophosphamide.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Mercaptopurine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be increased when combined with Cyclophosphamide.]
[L01CB02, teniposide, The metabolism of Teniposide can be increased when combined with Cyclophosphamide.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Cyclophosphamide.]
[G03BA03, testosterone, The metabolism of Cyclophosphamide can be increased when combined with Testosterone.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Tetracaine.]
[S03AA02, tetracycline, The metabolism of Cyclophosphamide can be decreased when combined with Tetracycline.]
[N05AE05, lurasidone, Cyclophosphamide may increase the neurotoxic activities of Lurasidone.]
[A04AD10, dronabinol, The metabolism of Cyclophosphamide can be decreased when combined with Dronabinol.]
[N04BC07, apomorphine, The metabolism of Cyclophosphamide can be decreased when combined with Apomorphine.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Thalidomide.]
[R03DA04, theophylline, The metabolism of Theophylline can be increased when combined with Cyclophosphamide.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Eribulin.]
[R06AD03, thiethylperazine, Thiethylperazine may increase the neurotoxic activities of Cyclophosphamide.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be increased when combined with Cyclophosphamide.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Cyclophosphamide.]
[N05CA19, thiopental, The metabolism of Thiopental can be decreased when combined with Cyclophosphamide.]
[N05AB08, thioproperazine, Cyclophosphamide may increase the neurotoxic activities of Thioproperazine.]
[N05AC02, thioridazine, The metabolism of Thioridazine can be decreased when combined with Cyclophosphamide.]
[N05AF04, thiothixene, Cyclophosphamide may increase the neurotoxic activities of Thiothixene.]
[N05AL03, tiapride, Cyclophosphamide may increase the neurotoxic activities of Tiapride.]
[B01AC05, ticlopidine, The metabolism of Cyclophosphamide can be decreased when combined with Ticlopidine.]
[S01ED01, timolol, The metabolism of Cyclophosphamide can be decreased when combined with Timolol.]
[A10BB05, tolazamide, The metabolism of Tolazamide can be decreased when combined with Cyclophosphamide.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be increased when combined with Cyclophosphamide.]
[N02AX02, tramadol, The metabolism of Tramadol can be increased when combined with Cyclophosphamide.]
[N06AF04, tranylcypromine, The metabolism of Cyclophosphamide can be decreased when combined with Tranylcypromine.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Cyclophosphamide.]
[N06AX05, trazodone, The metabolism of Cyclophosphamide can be decreased when combined with Trazodone.]
[L01XF01, tretinoin, The metabolism of Cyclophosphamide can be decreased when combined with Tretinoin.]
[S01BA05, triamcinolone, The metabolism of Cyclophosphamide can be increased when combined with Triamcinolone.]
[N05CD05, triazolam, The metabolism of Cyclophosphamide can be decreased when combined with Triazolam.]
[C03AA06, trichlormethiazide, The risk or severity of granulocytopenia can be increased when Trichlormethiazide is combined with Cyclophosphamide.]
[N05AB06, trifluoperazine, Cyclophosphamide may increase the neurotoxic activities of Trifluoperazine.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Cyclophosphamide.]
[N05AD02, trifluperidol, Cyclophosphamide may increase the neurotoxic activities of Trifluperidol.]
[N05AA05, triflupromazine, Triflupromazine may increase the neurotoxic activities of Cyclophosphamide.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Fluclorolone.]
[R03BA07, mometasone, The metabolism of Cyclophosphamide can be increased when combined with Mometasone.]
[R06AD01, trimeprazine, Cyclophosphamide may increase the neurotoxic activities of Alimemazine.]
[N03AC02, trimethadione, The metabolism of Trimethadione can be increased when combined with Cyclophosphamide.]
[J01EA01, trimethoprim, The metabolism of Cyclophosphamide can be decreased when combined with Trimethoprim.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Cyclophosphamide.]
[J01FA08, troleandomycin, The metabolism of Cyclophosphamide can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Vilazodone can be decreased when combined with Cyclophosphamide.]
[M03AA02, tubocurarine, Cyclophosphamide may increase the neurotoxic activities of Tubocurarine.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Cyclophosphamide.]
[L04AA26, belimumab, The risk or severity of leukopenia can be increased when Belimumab is combined with Cyclophosphamide.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be increased when combined with Cyclophosphamide.]
[L02BX03, abiraterone, The metabolism of Cyclophosphamide can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Cyclophosphamide can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Cyclophosphamide can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Cyclophosphamide can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Cyclophosphamide.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Cyclophosphamide.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Belatacept.]
[B01AF01, rivaroxaban, The metabolism of Cyclophosphamide can be decreased when combined with Rivaroxaban.]
[B01AC24, ticagrelor, The metabolism of Cyclophosphamide can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Cyclophosphamide can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Cyclophosphamide can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be increased when combined with Cyclophosphamide.]
[L01CA02, vincristine, The metabolism of Vincristine can be increased when combined with Cyclophosphamide.]
[L01CA03, vindesine, The metabolism of Vindesine can be increased when combined with Cyclophosphamide.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cyclophosphamide.]
[A11HA03, vitamin E, The metabolism of Cyclophosphamide can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The therapeutic efficacy of Warfarin can be increased when used in combination with Cyclophosphamide.]
[J05AF01, zidovudine, The metabolism of Cyclophosphamide can be decreased when combined with Zidovudine.]
[N05AF05, zuclopenthixol, The metabolism of Cyclophosphamide can be decreased when combined with Zuclopenthixol.]
[J05AE02, indinavir, The serum concentration of the active metabolites of Cyclophosphamide can be increased when Cyclophosphamide is used in combination with Indinavir.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be increased when combined with Cyclophosphamide.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be increased when combined with Cyclophosphamide.]
[L01ED01, crizotinib, The metabolism of Cyclophosphamide can be decreased when combined with Crizotinib.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Cyclophosphamide.]
[R03DC01, zafirlukast, The metabolism of Cyclophosphamide can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, The metabolism of Cyclophosphamide can be decreased when combined with Rabeprazole.]
[N05AE04, ziprasidone, The metabolism of Cyclophosphamide can be decreased when combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Cyclophosphamide can be decreased when combined with Drospirenone.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cyclophosphamide.]
[N02BA01, aspirin, The metabolism of Cyclophosphamide can be increased when combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be increased when combined with Cyclophosphamide.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be decreased when combined with Cyclophosphamide.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cyclophosphamide.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Cyclophosphamide.]
[J02AC03, voriconazole, The metabolism of Cyclophosphamide can be decreased when combined with Voriconazole.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Cyclophosphamide.]
[L01EK01, axitinib, The metabolism of Axitinib can be increased when combined with Cyclophosphamide.]
[R07AX02, ivacaftor, The metabolism of Cyclophosphamide can be decreased when combined with Ivacaftor.]
[H02AB11, prednylidene, The metabolism of Cyclophosphamide can be increased when combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Cyclophosphamide.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Azacitidine.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Cyclophosphamide.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Cyclophosphamide.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Cyclophosphamide.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Cyclophosphamide.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cyclophosphamide.]
[L01FD02, pertuzumab, The risk or severity of cardiotoxicity can be increased when Cyclophosphamide is combined with Pertuzumab.]
[A08AA11, lorcaserin, The metabolism of Cyclophosphamide can be decreased when combined with Lorcaserin.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Carfilzomib.]
[V03AX03, cobicistat, The metabolism of Cyclophosphamide can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Cyclophosphamide can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Cyclophosphamide can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be increased when combined with Cyclophosphamide.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Cyclophosphamide.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Aldosterone.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be increased when combined with Cyclophosphamide.]
[N05CA04, barbital, The metabolism of Cyclophosphamide can be increased when combined with Barbital.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may decrease the cardiotoxic activities of Cyclophosphamide.]
[J05AE04, nelfinavir, The serum concentration of the active metabolites of Cyclophosphamide can be increased when Cyclophosphamide is used in combination with Nelfinavir.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Bendamustine.]
[C08CA13, lercanidipine, The metabolism of Cyclophosphamide can be decreased when combined with Lercanidipine.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Cyclophosphamide.]
[N03AX22, perampanel, The metabolism of Perampanel can be increased when combined with Cyclophosphamide.]
[L04AA29, tofacitinib, Cyclophosphamide may increase the immunosuppressive activities of Tofacitinib.]
[N01AA01, ethyl ether, Cyclophosphamide may increase the neurotoxic activities of Diethyl ether.]
[L01EX07, cabozantinib, The metabolism of Cyclophosphamide can be decreased when combined with Cabozantinib.]
[H01CB05, pasireotide, The metabolism of Cyclophosphamide can be decreased when combined with Pasireotide.]
[G04BE03, sildenafil, The metabolism of Cyclophosphamide can be decreased when combined with Sildenafil.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be increased when combined with Cyclophosphamide.]
[B01AF02, apixaban, The metabolism of Cyclophosphamide can be decreased when combined with Apixaban.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be increased when combined with Cyclophosphamide.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Cyclophosphamide can be increased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The risk or severity of granulocytopenia can be increased when Bendroflumethiazide is combined with Cyclophosphamide.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be increased when combined with Cyclophosphamide.]
[G03XC05, ospemifene, The metabolism of Cyclophosphamide can be decreased when combined with Ospemifene.]
[N05AD07, benperidol, Cyclophosphamide may increase the neurotoxic activities of Benperidol.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Dimethyl fumarate.]
[M04AB03, benzbromarone, The metabolism of Cyclophosphamide can be decreased when combined with Benzbromarone.]
[A06AX06, tegaserod, The metabolism of Cyclophosphamide can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Benzocaine.]
[L03AA12, ancestim, The risk or severity of pulmonary toxicity can be increased when Ancestim is combined with Cyclophosphamide.]
[M01AH01, celecoxib, The risk or severity of methemoglobinemia can be increased when Celecoxib is combined with Cyclophosphamide.]
[L04AA18, everolimus, The metabolism of Everolimus can be increased when combined with Cyclophosphamide.]
[L01EC02, dabrafenib, The serum concentration of Cyclophosphamide can be decreased when it is combined with Dabrafenib.]
[L01EE01, trametinib, The metabolism of Cyclophosphamide can be decreased when combined with Trametinib.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be increased when combined with Cyclophosphamide.]
[C02KX05, riociguat, The metabolism of Riociguat can be increased when combined with Cyclophosphamide.]
[L03AA14, lipegfilgrastim, Cyclophosphamide may increase the myelosuppressive activities of Lipegfilgrastim.]
[L01EL01, ibrutinib, The metabolism of Cyclophosphamide can be decreased when combined with Ibrutinib.]
[N06AX26, vortioxetine, The metabolism of Cyclophosphamide can be decreased when combined with Vortioxetine.]
[G03AC08, etonogestrel, The metabolism of Etonogestrel can be increased when combined with Cyclophosphamide.]
[N03AF04, eslicarbazepine, The metabolism of Cyclophosphamide can be increased when combined with Eslicarbazepine.]
[D01AC18, luliconazole, The serum concentration of Cyclophosphamide can be increased when it is combined with Luliconazole.]
[J05AP05, simeprevir, The metabolism of Cyclophosphamide can be decreased when combined with Simeprevir.]
[A10BK01, dapagliflozin, The metabolism of Cyclophosphamide can be decreased when combined with Dapagliflozin.]
[N05CH03, tasimelteon, The metabolism of Cyclophosphamide can be decreased when combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Cyclophosphamide can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Cyclophosphamide can be increased when combined with Apremilast.]
[L02BG02, formestane, The metabolism of Cyclophosphamide can be increased when combined with Formestane.]
[S03BA03, betamethasone, The metabolism of Cyclophosphamide can be increased when combined with Betamethasone.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Cyclophosphamide.]
[V03AB34, fomepizole, The metabolism of Cyclophosphamide can be decreased when combined with Fomepizole.]
[C10AB02, bezafibrate, The metabolism of Cyclophosphamide can be decreased when combined with Bezafibrate.]
[L04AC11, siltuximab, The metabolism of Cyclophosphamide can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be increased when combined with Cyclophosphamide.]
[B01AC26, vorapaxar, The metabolism of Cyclophosphamide can be decreased when combined with Vorapaxar.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Vedolizumab.]
[B01AA07, acenocoumarol, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Cyclophosphamide.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Belinostat.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be increased when combined with Cyclophosphamide.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be increased when combined with Cyclophosphamide.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Antilymphocyte immunoglobulin (horse).]
[S01AA13, fusidic acid, The metabolism of Cyclophosphamide can be decreased when combined with Fusidic acid.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be increased when combined with Cyclophosphamide.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Peginterferon beta-1a.]
[N05CM19, suvorexant, The metabolism of Cyclophosphamide can be decreased when combined with Suvorexant.]
[J01XA05, oritavancin, The metabolism of Cyclophosphamide can be increased when combined with Oritavancin.]
[N05AA04, acepromazine, Cyclophosphamide may increase the neurotoxic activities of Acepromazine.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Decitabine.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Pirfenidone.]
[L01EX09, nintedanib, The metabolism of Cyclophosphamide can be decreased when combined with Nintedanib.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Blinatumomab.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be increased when combined with Cyclophosphamide.]
[L01XK01, olaparib, The metabolism of Olaparib can be increased when combined with Cyclophosphamide.]
[B01AA01, dicumarol, The therapeutic efficacy of Dicoumarol can be increased when used in combination with Cyclophosphamide.]
[B01AF03, edoxaban, The risk or severity of bleeding can be increased when Edoxaban is combined with Cyclophosphamide.]
[N06AX11, mirtazapine, The metabolism of Cyclophosphamide can be decreased when combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Cyclophosphamide can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be increased when combined with Cyclophosphamide.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be increased when combined with Cyclophosphamide.]
[J05AP07, daclatasvir, The metabolism of Cyclophosphamide can be decreased when combined with Daclatasvir.]
[N02BE01, acetaminophen, The metabolism of Cyclophosphamide can be increased when combined with Acetaminophen.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Cyclophosphamide.]
[B01AA11, tioclomarol, The therapeutic efficacy of Tioclomarol can be increased when used in combination with Cyclophosphamide.]
[J05AP06, asunaprevir, The serum concentration of the active metabolites of Cyclophosphamide can be increased when Cyclophosphamide is used in combination with Asunaprevir.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Cyclophosphamide.]
[N05AX16, brexpiprazole, Cyclophosphamide may increase the neurotoxic activities of Brexpiprazole.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be increased when combined with Cyclophosphamide.]
[N05AX15, cariprazine, Cyclophosphamide may increase the neurotoxic activities of Cariprazine.]
[S01EC01, acetazolamide, The metabolism of Cyclophosphamide can be decreased when combined with Acetazolamide.]
[N05AB07, acetophenazine, Cyclophosphamide may increase the neurotoxic activities of Acetophenazine.]
[A02BC03, lansoprazole, The metabolism of Cyclophosphamide can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be increased when combined with Cyclophosphamide.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Mepolizumab.]
[J02AC05, isavuconazole, The metabolism of Cyclophosphamide can be increased when combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be increased when combined with Cyclophosphamide.]
[J05AF13, tenofovir alafenamide, The metabolism of Cyclophosphamide can be decreased when combined with Tenofovir alafenamide.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be increased when combined with Cyclophosphamide.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be increased when combined with Cyclophosphamide.]
[L01ED03, alectinib, The metabolism of Alectinib can be increased when combined with Cyclophosphamide.]
[B01AC27, selexipag, The metabolism of Selexipag can be increased when combined with Cyclophosphamide.]
[A10BB31, acetohexamide, The metabolism of Cyclophosphamide can be decreased when combined with Acetohexamide.]
[M04AB05, lesinurad, The metabolism of Cyclophosphamide can be increased when combined with Lesinurad.]
[J05AP10, elbasvir, The metabolism of Cyclophosphamide can be decreased when combined with Elbasvir.]
[N05CA05, aprobarbital, The metabolism of Cyclophosphamide can be increased when combined with Aprobarbital.]
[N03AX23, brivaracetam, The metabolism of Cyclophosphamide can be decreased when combined with Brivaracetam.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Ixekizumab.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be increased when combined with Cyclophosphamide.]
[R06AB01, brompheniramine, The metabolism of Cyclophosphamide can be decreased when combined with Brompheniramine.]
[N06AA19, amineptin, Cyclophosphamide may increase the neurotoxic activities of Amineptine.]
[C08CA01, amlodipine, The metabolism of Amlodipine can be increased when combined with Cyclophosphamide.]
[N05AX17, pimavanserin, The metabolism of Cyclophosphamide can be decreased when combined with Pimavanserin.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Bupivacaine.]
[N07BC01, buprenorphine, The metabolism of Cyclophosphamide can be decreased when combined with Buprenorphine.]
[N05BE01, buspirone, The metabolism of Cyclophosphamide can be decreased when combined with Buspirone.]
[L01AB01, busulfan, The metabolism of Busulfan can be increased when combined with Cyclophosphamide.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Arsenic trioxide.]
[P01BE02, artemether, The metabolism of Cyclophosphamide can be decreased when combined with Artemether.]
[M02AA03, clofezone, The metabolism of Cyclophosphamide can be decreased when combined with Rabeprazole.]
[S01GX07, azelastine, The metabolism of Cyclophosphamide can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Cyclophosphamide can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The metabolism of Cyclophosphamide can be decreased when combined with Azithromycin.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Brodalumab.]
[L01EF02, ribociclib, The metabolism of Cyclophosphamide can be decreased when combined with Ribociclib.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Cyclophosphamide.]
[N07XX16, deutetrabenazine, The metabolism of Cyclophosphamide can be decreased when combined with Deutetrabenazine.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Oxybuprocaine.]
[D05AX03, calcitriol, The metabolism of Cyclophosphamide can be increased when combined with Calcitriol.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Cyclophosphamide.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Linezolid.]
[J05AE09, tipranavir, The serum concentration of the active metabolites of Cyclophosphamide can be increased when Cyclophosphamide is used in combination with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Cyclophosphamide can be decreased when combined with Valbenazine.]
[L04AB02, infliximab, The metabolism of Cyclophosphamide can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Cyclophosphamide can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be increased when combined with Cyclophosphamide.]
[L04AC14, sarilumab, The metabolism of Cyclophosphamide can be increased when combined with Sarilumab.]
[J01MA23, delafloxacin, The metabolism of Cyclophosphamide can be increased when combined with Delafloxacin.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Cyclophosphamide.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Guselkumab.]
[D01AC10, bifonazole, The metabolism of Cyclophosphamide can be decreased when combined with Bifonazole.]
[L01BC06, capecitabine, The metabolism of Cyclophosphamide can be decreased when combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be increased when combined with Cyclophosphamide.]
[L01EH02, neratinib, The metabolism of Neratinib can be increased when combined with Cyclophosphamide.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Vorinostat.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be increased when combined with Cyclophosphamide.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be increased when combined with Cyclophosphamide.]
[A02BX12, bismuth subnitrate, Cyclophosphamide may increase the neurotoxic activities of Bismuth subnitrate.]
[J05AG03, efavirenz, The metabolism of Cyclophosphamide can be decreased when combined with Efavirenz.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Cyclophosphamide.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Cyclophosphamide.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Cyclophosphamide.]
[N05AD06, bromperidol, Cyclophosphamide may increase the neurotoxic activities of Bromperidol.]
[R03BA02, budesonide, The metabolism of Cyclophosphamide can be increased when combined with Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Cyclophosphamide.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be increased when combined with Cyclophosphamide.]
[J05AX18, letermovir, The metabolism of Cyclophosphamide can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, Cyclophosphamide may increase the neurotoxic activities of Butriptyline.]
[C01AA02, acetyldigoxins, Acetyldigoxin may decrease the cardiotoxic activities of Cyclophosphamide.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Capsaicin.]
[L02BB05, apalutamide, The serum concentration of Cyclophosphamide can be increased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Cyclophosphamide can be increased when combined with Carbamazepine.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Cyclophosphamide.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be decreased when combined with Cyclophosphamide.]
[B02BX09, fostamatinib, The metabolism of Cyclophosphamide can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The metabolism of Cyclophosphamide can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The metabolism of Cyclophosphamide can be increased when combined with Avatrombopag.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Baricitinib.]
[H01CC03, elagolix, The metabolism of Elagolix can be increased when combined with Cyclophosphamide.]
[L01XX62, ivosidenib, The metabolism of Cyclophosphamide can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Cyclophosphamide can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Cyclophosphamide can be increased when combined with Tecovirimat.]
[J05AG06, doravirine, The metabolism of Cyclophosphamide can be decreased when combined with Doravirine.]
[L01EM04, duvelisib, The metabolism of Cyclophosphamide can be decreased when combined with Duvelisib.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be increased when combined with Cyclophosphamide.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Cyclophosphamide.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Chloroprocaine.]
[M01AC05, lornoxicam, The metabolism of Lornoxicam can be decreased when combined with Cyclophosphamide.]
[M03BA02, carisoprodol, The metabolism of Cyclophosphamide can be decreased when combined with Carisoprodol.]
[L01ED05, lorlatinib, The metabolism of Cyclophosphamide can be increased when combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Cyclophosphamide can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Cyclophosphamide.]
[L01EX13, gilteritinib, The metabolism of Cyclophosphamide can be decreased when combined with Gilteritinib.]
[L01XJ03, glasdegib, The metabolism of Glasdegib can be increased when combined with Cyclophosphamide.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Ravulizumab.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Cyclophosphamide.]
[B01AC23, cilostazol, The metabolism of Cyclophosphamide can be decreased when combined with Cilostazol.]
[P02BX04, triclabendazole, The metabolism of Cyclophosphamide can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The metabolism of Cyclophosphamide can be increased when combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Siponimod can be increased when combined with Cyclophosphamide.]
[J01FA09, clarithromycin, The metabolism of Cyclophosphamide can be decreased when combined with Clarithromycin.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be increased when combined with Cyclophosphamide.]
[N05BA09, clobazam, The metabolism of Cyclophosphamide can be increased when combined with Clobazam.]
[H02AB14, cloprednol, The metabolism of Cyclophosphamide can be increased when combined with Cloprednol.]
[C09CA06, candesartan, The metabolism of Cyclophosphamide can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Cyclophosphamide.]
[H02AB17, cortivazol, The metabolism of Cyclophosphamide can be increased when combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Risankizumab.]
[L01EM03, alpelisib, The serum concentration of Cyclophosphamide can be decreased when it is combined with Alpelisib.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be increased when combined with Cyclophosphamide.]
[N05AA06, cyamemazine, Cyclophosphamide may increase the neurotoxic activities of Cyamemazine.]
[M03BX08, cyclobenzaprine, Cyclophosphamide may increase the neurotoxic activities of Cyclobenzaprine.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Upadacitinib.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Cyclophosphamide.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be increased when combined with Cyclophosphamide.]
[N07XX11, pitolisant, The serum concentration of Cyclophosphamide can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Cyclophosphamide can be decreased when combined with Pretomanid.]
[J01XX12, lefamulin, The serum concentration of Cyclophosphamide can be increased when it is combined with Lefamulin.]
[N04CX01, istradefylline, The metabolism of Cyclophosphamide can be decreased when combined with Istradefylline.]
[C03AA09, cyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Cyclophosphamide.]
[J01DB01, cephalexin, The metabolism of Cyclophosphamide can be decreased when combined with Cephalexin.]
[J01DB09, cephradine, The metabolism of Cyclophosphamide can be increased when combined with Cefradine.]
[H02AB13, deflazacort, The metabolism of Cyclophosphamide can be increased when combined with Deflazacort.]
[G03DB05, demegestone, The metabolism of Demegestone can be increased when combined with Cyclophosphamide.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Cyclophosphamide.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Diroximel fumarate.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be increased when combined with Cyclophosphamide.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be increased when combined with Cyclophosphamide.]
[B06AX03, voxelotor, The serum concentration of Cyclophosphamide can be increased when it is combined with Voxelotor.]
[N03AX25, cenobamate, The serum concentration of Cyclophosphamide can be decreased when it is combined with Cenobamate.]
[L01EX18, avapritinib, The metabolism of Cyclophosphamide can be decreased when combined with Avapritinib.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be decreased when it is combined with Cyclophosphamide.]
[L01XX72, tazemetostat, The metabolism of Cyclophosphamide can be decreased when combined with Tazemetostat.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Teprotumumab.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be decreased when it is combined with Cyclophosphamide.]
[M01AX21, diacetylrhein, The metabolism of Cyclophosphamide can be decreased when combined with Diacerein.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be increased when combined with Cyclophosphamide.]
[J05AB16, remdesivir, The metabolism of Cyclophosphamide can be decreased when combined with Remdesivir.]
[H02CA02, osilodrostat, The serum concentration of Cyclophosphamide can be increased when it is combined with Osilodrostat.]
[J05AE05, amprenavir, The serum concentration of the active metabolites of Cyclophosphamide can be increased when Cyclophosphamide is used in combination with Amprenavir.]
[G04CB02, dutasteride, The metabolism of Cyclophosphamide can be decreased when combined with Dutasteride.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Ozanimod.]
[L01EE04, selumetinib, The metabolism of Cyclophosphamide can be decreased when combined with Selumetinib.]
[G03DB08, dienogest, The metabolism of Dienogest can be increased when combined with Cyclophosphamide.]
[N02CC06, eletriptan, The metabolism of Cyclophosphamide can be increased when combined with Eletriptan.]
[M01AH02, rofecoxib, The metabolism of Cyclophosphamide can be increased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Cyclophosphamide can be increased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Cyclophosphamide can be increased when combined with Clevidipine.]
[C01BD07, dronedarone, The serum concentration of Cyclophosphamide can be increased when it is combined with Dronedarone.]
[J01FA13, dirithromycin, The metabolism of Cyclophosphamide can be decreased when combined with Dirithromycin.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Cyclophosphamide.]
[S03AA08, chloramphenicol, The metabolism of Cyclophosphamide can be decreased when combined with Chloramphenicol.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Cyclophosphamide.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be decreased when it is combined with Cyclophosphamide.]
[D07XB03, fluprednidene, The metabolism of Cyclophosphamide can be increased when combined with Fluprednidene.]
[P01BE01, artemisinin, The metabolism of Cyclophosphamide can be decreased when combined with Artemisinin.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Cyclophosphamide.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Cyclophosphamide.]
[N05CM02, chlormethiazole, The metabolism of Cyclophosphamide can be decreased when combined with Clomethiazole.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Cyclophosphamide is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Stepronin.]
[C08CA17, levamlodipine, The metabolism of Cyclophosphamide can be decreased when combined with Levamlodipine.]
[R06AX22, ebastine, The metabolism of Cyclophosphamide can be decreased when combined with Ebastine.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Cyclophosphamide.]
[L04AC19, satralizumab, The serum concentration of Cyclophosphamide can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The serum concentration of Oliceridine can be decreased when it is combined with Cyclophosphamide.]
[P01BA01, chloroquine, The metabolism of Cyclophosphamide can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The metabolism of Cyclophosphamide can be increased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The risk or severity of granulocytopenia can be increased when Chlorothiazide is combined with Cyclophosphamide.]
[R06AB04, chlorpheniramine, The metabolism of Cyclophosphamide can be decreased when combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Cyclophosphamide can be increased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The metabolism of Chlorpropamide can be decreased when combined with Cyclophosphamide.]
[N05AF03, chlorprothixene, Cyclophosphamide may increase the neurotoxic activities of Chlorprothixene.]
[C03BA04, chlorthalidone, The risk or severity of granulocytopenia can be increased when Chlorthalidone is combined with Cyclophosphamide.]
[M03BB03, chlorzoxazone, The metabolism of Cyclophosphamide can be decreased when combined with Chlorzoxazone.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be increased when combined with Cyclophosphamide.]
[M01AB08, etodolac, The metabolism of Etodolac can be decreased when combined with Cyclophosphamide.]
[B06AC06, berotralstat, The serum concentration of Cyclophosphamide can be increased when it is combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Cyclophosphamide can be decreased when combined with Lonafarnib.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Fludarabine.]
[L02BX04, relugolix, The metabolism of Cyclophosphamide can be decreased when combined with Relugolix.]
[L01FX21, naxitamab, Cyclophosphamide may increase the neurotoxic activities of Naxitamab.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Cyclophosphamide can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The metabolism of Cyclophosphamide can be decreased when combined with Tepotinib.]
[N03AX10, felbamate, The metabolism of Cyclophosphamide can be increased when combined with Felbamate.]
[G04CB01, finasteride, The metabolism of Cyclophosphamide can be decreased when combined with Finasteride.]
[R03BA03, flunisolide, The metabolism of Cyclophosphamide can be increased when combined with Flunisolide.]
[S02BA08, fluocinolone acetonide, The metabolism of Cyclophosphamide can be increased when combined with Fluocinolone acetonide.]
[R03CC15, formoterol, The metabolism of Cyclophosphamide can be decreased when combined with Formoterol.]
[L04AA50, ponesimod, The metabolism of Cyclophosphamide can be decreased when combined with Ponesimod.]
[S01LA08, bevacizumab, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Cyclophosphamide.]
[L01EK03, tivozanib, The metabolism of Tivozanib can be increased when combined with Cyclophosphamide.]
[L03AB10, peginterferon alfa-2b, The metabolism of Cyclophosphamide can be increased when combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, The metabolism of Cyclophosphamide can be decreased when combined with Cimetidine.]
[N07CA02, cinnarizine, The metabolism of Cyclophosphamide can be decreased when combined with Cinnarizine.]
[L01XX73, sotorasib, The serum concentration of Cyclophosphamide can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Cyclophosphamide can be decreased when combined with Infigratinib.]
[S03AA07, ciprofloxacin, The metabolism of Cyclophosphamide can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The metabolism of Cyclophosphamide can be decreased when combined with Cisplatin.]
[N06AB04, citalopram, The metabolism of Cyclophosphamide can be decreased when combined with Citalopram.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Pegcetacoplan.]
[H01AC07, somapacitan, The metabolism of Cyclophosphamide can be decreased when combined with Somapacitan.]
[C03DA05, finerenone, The metabolism of Finerenone can be increased when combined with Cyclophosphamide.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Belumosudil.]
[P01CA03, fexinidazole, The metabolism of Cyclophosphamide can be decreased when combined with Fexinidazole.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Anifrolumab.]
[L01XX74, belzutifan, The serum concentration of Cyclophosphamide can be decreased when it is combined with Belzutifan.]
[L01EB10, mobocertinib, The serum concentration of Cyclophosphamide can be decreased when it is combined with Mobocertinib.]
[L04AA59, avacopan, The metabolism of Cyclophosphamide can be decreased when combined with Avacopan.]
[M01AG01, mefenamic acid, The metabolism of Mefenamic acid can be decreased when combined with Cyclophosphamide.]
[A10BB12, glimepiride, The metabolism of Cyclophosphamide can be decreased when combined with Glimepiride.]
[A10BB08, gliquidone, The metabolism of Gliquidone can be decreased when combined with Cyclophosphamide.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Cyclophosphamide.]
[N06AX25, St. John's wort extract, The metabolism of Cyclophosphamide can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Cyclophosphamide can be increased when it is combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Ropeginterferon alfa-2b.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Cyclophosphamide.]
[J04BA01, clofazimine, The metabolism of Cyclophosphamide can be decreased when combined with Clofazimine.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Cyclophosphamide.]
[C10AB01, clofibrate, The metabolism of Cyclophosphamide can be increased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Cyclophosphamide can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Cyclophosphamide can be increased when it is combined with Pacritinib.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be increased when combined with Cyclophosphamide.]
[N03AE01, clonazepam, The metabolism of Clonazepam can be increased when combined with Cyclophosphamide.]
[S01EA04, clonidine, The metabolism of Clonidine can be increased when combined with Cyclophosphamide.]
[C01EB24, mavacamten, The serum concentration of Cyclophosphamide can be decreased when it is combined with Mavacamten.]
[A02BC08, vonoprazan, The metabolism of Cyclophosphamide can be decreased when combined with Vonoprazan.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Deucravacitinib.]
[N05AH06, clothiapine, Cyclophosphamide may increase the neurotoxic activities of Clothiapine.]
[H01CC04, linzagolix, The serum concentration of Cyclophosphamide can be increased when it is combined with Linzagolix.]
[N05BA21, clotiazepam, The metabolism of Cyclophosphamide can be decreased when combined with Clotiazepam.]
[A04AA01, ondansetron, The metabolism of Cyclophosphamide can be decreased when combined with Ondansetron.]
[J05AX31, lenacapavir, The metabolism of Cyclophosphamide can be decreased when combined with Lenacapavir.]
[N05AH02, clozapine, The risk or severity of neutropenia can be increased when Cyclophosphamide is combined with Clozapine.]
[H01AC08, somatrogon, The metabolism of Cyclophosphamide can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Cocaine.]
[L04AC21, bimekizumab, The metabolism of Cyclophosphamide can be increased when combined with Bimekizumab.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Leflunomide.]
[A10BX03, nateglinide, The metabolism of Cyclophosphamide can be decreased when combined with Nateglinide.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Nelarabine.]
[J01FA15, telithromycin, The metabolism of Cyclophosphamide can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of bleeding can be increased when Indobufen is combined with Cyclophosphamide.]
[M01AH03, valdecoxib, The metabolism of Cyclophosphamide can be decreased when combined with Valdecoxib.]
[C01AA06, lanatoside C, Lanatoside C may decrease the cardiotoxic activities of Cyclophosphamide.]
[A03AX10, isometheptene, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Isometheptene.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be increased when combined with Cyclophosphamide.]
[M01AH04, parecoxib, The metabolism of Parecoxib can be decreased when combined with Cyclophosphamide.]
[J02AC02, itraconazole, The metabolism of Cyclophosphamide can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Cyclophosphamide.]
[N05BA10, ketazolam, The metabolism of Cyclophosphamide can be decreased when combined with Ketazolam.]
[L01EA01, imatinib, The serum concentration of Cyclophosphamide can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Cyclophosphamide can be decreased when combined with Posaconazole.]
[A02BC05, esomeprazole, The metabolism of Cyclophosphamide can be decreased when combined with Esomeprazole.]
[V03AF07, rasburicase, The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Cyclophosphamide.]
[B03XA02, darbepoetin alfa, The risk or severity of pulmonary toxicity can be increased when Darbepoetin alfa is combined with Cyclophosphamide.]
[S01BA03, cortisone, The metabolism of Cyclophosphamide can be increased when combined with Cortisone.]
[R06AX13, loratadine, The metabolism of Cyclophosphamide can be decreased when combined with Loratadine.]
[C08CA11, manidipine, The metabolism of Cyclophosphamide can be decreased when combined with Manidipine.]
[H02AB15, meprednisone, The metabolism of Cyclophosphamide can be increased when combined with Meprednisone.]
[R06AD07, mequitazine, The metabolism of Cyclophosphamide can be decreased when combined with Mequitazine.]
[R06AE03, cyclizine, The metabolism of Cyclophosphamide can be decreased when combined with Cyclizine.]
[C03DA04, eplerenone, The metabolism of Cyclophosphamide can be decreased when combined with Eplerenone.]
[N05AD03, metylperon, Cyclophosphamide may increase the neurotoxic activities of Melperone.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Cyclophosphamide.]
[C03AA07, cyclopenthiazide, The risk or severity of granulocytopenia can be increased when Cyclopenthiazide is combined with Cyclophosphamide.]
[J01FA03, midecamycin, The metabolism of Cyclophosphamide can be decreased when combined with Midecamycin.]
[J04AB01, cycloserine, Cycloserine may increase the neurotoxic activities of Cyclophosphamide.]
[S01XA18, cyclosporine, The serum concentration of Cyclosporine can be decreased when it is combined with Cyclophosphamide.]
[N06AG02, moclobemide, The metabolism of Cyclophosphamide can be decreased when combined with Moclobemide.]
[N06BA07, modafinil, The metabolism of Cyclophosphamide can be increased when combined with Modafinil.]
[C10AA07, rosuvastatin, The metabolism of Cyclophosphamide can be decreased when combined with Rosuvastatin.]
[C03XA02, conivaptan, The metabolism of Cyclophosphamide can be decreased when combined with Conivaptan.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Cytarabine.]
[G04BE09, vardenafil, The metabolism of Cyclophosphamide can be decreased when combined with Vardenafil.]
[M01AH05, etoricoxib, The metabolism of Cyclophosphamide can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Dacarbazine.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Dactinomycin.]
[G03XA01, danazol, The metabolism of Cyclophosphamide can be decreased when combined with Danazol.]
[J04BA02, dapsone, The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Cyclophosphamide.]
[L01DB02, daunorubicin, The metabolism of Cyclophosphamide can be decreased when combined with Daunorubicin.]
[A04AD11, nabilone, The metabolism of Cyclophosphamide can be decreased when combined with Nabilone.]
[M01AX01, nabumetone, The metabolism of Cyclophosphamide can be decreased when combined with Nabumetone.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Cyclophosphamide.]
[N06AX06, nefazodone, The metabolism of Cyclophosphamide can be decreased when combined with Nefazodone.]
[L02BB02, nilutamide, The metabolism of Cyclophosphamide can be decreased when combined with Nilutamide.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be increased when combined with Cyclophosphamide.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Fondaparinux is combined with Cyclophosphamide.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cyclophosphamide.]
[N06AB10, escitalopram, The metabolism of Escitalopram can be decreased when combined with Cyclophosphamide.]
[N06AA01, desipramine, The metabolism of Cyclophosphamide can be decreased when combined with Desipramine.]
[C01AA07, deslanoside, Deslanoside may decrease the cardiotoxic activities of Cyclophosphamide.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Desoximetasone.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Cyclophosphamide.]
[N03AF02, oxcarbazepine, The metabolism of Cyclophosphamide can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Cyclophosphamide can be increased when combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Cyclophosphamide can be decreased when combined with Oxybutynin.]
[L04AB04, adalimumab, The metabolism of Cyclophosphamide can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Cyclophosphamide can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, The metabolism of Cyclophosphamide can be decreased when combined with Amphetamine.]
[R05DA09, dextromethorphan, The metabolism of Cyclophosphamide can be decreased when combined with Dextromethorphan.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be increased when combined with Cyclophosphamide.]
[N06AB05, paroxetine, The metabolism of Cyclophosphamide can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Cyclophosphamide can be decreased when combined with Clopidogrel.]
[N05BA01, diazepam, The metabolism of Cyclophosphamide can be decreased when combined with Diazepam.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Phenol.]
[N06AA08, dibenzepin, Cyclophosphamide may increase the neurotoxic activities of Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Cinchocaine.]
[S01BC03, diclofenac, The metabolism of Cyclophosphamide can be decreased when combined with Diclofenac.]
[J01CF01, dicloxacillin, The metabolism of Cyclophosphamide can be increased when combined with Dicloxacillin.]
[J05AF02, didanosine, Cyclophosphamide may increase the neurotoxic activities of Didanosine.]
[A10BG03, pioglitazone, The metabolism of Pioglitazone can be increased when combined with Cyclophosphamide.]
[N05AD05, pipamperone, Cyclophosphamide may increase the neurotoxic activities of Pipamperone.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be increased when combined with Cyclophosphamide.]
[L01EB02, erlotinib, The serum concentration of Erlotinib can be decreased when it is combined with Cyclophosphamide.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Pirarubicin.]
[L03AA13, pegfilgrastim, The risk or severity of pulmonary toxicity can be increased when Pegfilgrastim is combined with Cyclophosphamide.]
[L02AA01, diethylstilbestrol, The metabolism of Cyclophosphamide can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Cyclophosphamide can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The metabolism of Cyclophosphamide can be increased when combined with Difluocortolone.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be increased when combined with Cyclophosphamide.]
[C01AA05, digoxin, Digoxin may decrease the cardiotoxic activities of Cyclophosphamide.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cyclophosphamide.]
[C04AE04, dihydroergocristine, The metabolism of Cyclophosphamide can be decreased when combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be increased when combined with Cyclophosphamide.]
[N02AA03, hydromorphone, The metabolism of Cyclophosphamide can be decreased when combined with Hydromorphone.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Cyclophosphamide.]
[J05AE08, atazanavir, The serum concentration of the active metabolites of Cyclophosphamide can be increased when Cyclophosphamide is used in combination with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Treprostinil can be increased when combined with Cyclophosphamide.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Cyclophosphamide can be decreased when combined with Diltiazem.]
[M02AX03, dimethyl sulfoxide, The metabolism of Cyclophosphamide can be decreased when combined with Dimethyl sulfoxide.]
[C05CA03, diosmin, The metabolism of Cyclophosphamide can be decreased when combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Diphenhydramine.]
[N05CD10, quazepam, The metabolism of Cyclophosphamide can be decreased when combined with Quazepam.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Dipyridamole is combined with Cyclophosphamide.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cyclophosphamide.]
[N06AA23, quinupramine, Cyclophosphamide may increase the neurotoxic activities of Quinupramine.]
[A03FA02, cisapride, The metabolism of Cyclophosphamide can be decreased when combined with Cisapride.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be increased when combined with Cyclophosphamide.]
[N05AL04, remoxipride, Remoxipride may increase the neurotoxic activities of Cyclophosphamide.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Natalizumab.]
[P03AA04, disulfiram, The metabolism of Cyclophosphamide can be decreased when combined with Disulfiram.]
[S02AA12, rifamycin SV, The metabolism of Cyclophosphamide can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Cyclophosphamide can be increased when combined with Rifapentine.]
[N05AX08, risperidone, The metabolism of Cyclophosphamide can be decreased when combined with Risperidone.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Cyclophosphamide.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Ropivacaine.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be increased when combined with Cyclophosphamide.]
[A04AD12, aprepitant, The metabolism of Cyclophosphamide can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be increased when combined with Cyclophosphamide.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be increased when combined with Cyclophosphamide.]
[J05AE07, fosamprenavir, The serum concentration of the active metabolites of Cyclophosphamide can be increased when Cyclophosphamide is used in combination with Fosamprenavir.]
[G04BE08, tadalafil, The metabolism of Cyclophosphamide can be decreased when combined with Tadalafil.]
[S01BC05, ketorolac, The metabolism of Ketorolac can be increased when combined with Cyclophosphamide.]
[C02KX02, ambrisentan, The metabolism of Cyclophosphamide can be decreased when combined with Ambrisentan.]
[C01EB18, ranolazine, The metabolism of Ranolazine can be increased when combined with Cyclophosphamide.]
[R03AC12, salmeterol, The metabolism of Cyclophosphamide can be decreased when combined with Salmeterol.]
[A03FA03, domperidone, The metabolism of Cyclophosphamide can be decreased when combined with Domperidone.]
[N06AA16, dothiepin, The metabolism of Dosulepin can be decreased when combined with Cyclophosphamide.]
[N06AA12, doxepin, The metabolism of Doxepin can be decreased when combined with Cyclophosphamide.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be increased when combined with Cyclophosphamide.]
[N06AB06, sertraline, The metabolism of Cyclophosphamide can be decreased when combined with Sertraline.]
[N01AB08, sevoflurane, The metabolism of Cyclophosphamide can be decreased when combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the neurotoxic activities of Cyclophosphamide.]
[C10AA01, simvastatin, The metabolism of Cyclophosphamide can be decreased when combined with Simvastatin.]
[N05AL02, sultopride, Cyclophosphamide may increase the neurotoxic activities of Sultopride.]
[H01AA01, corticotropin, The metabolism of Cyclophosphamide can be increased when combined with Corticotropin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Temozolomide.]
[M01AC02, tenoxicam, The metabolism of Cyclophosphamide can be decreased when combined with Tenoxicam.]
[D01BA02, terbinafine, The metabolism of Cyclophosphamide can be increased when combined with Terbinafine.]
[N05AB05, thiopropazate, Cyclophosphamide may increase the neurotoxic activities of Thiopropazate.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be increased when combined with Cyclophosphamide.]
[N03AX11, topiramate, The metabolism of Cyclophosphamide can be increased when combined with Topiramate.]
[C03CA04, torsemide, The metabolism of Cyclophosphamide can be decreased when combined with Torasemide.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Cyclophosphamide.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Trilostane.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Cyclophosphamide.]
[N05AL06, veralipride, Cyclophosphamide may increase the neurotoxic activities of Veralipride.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be increased when combined with Cyclophosphamide.]
[S01GX10, epinastine, The metabolism of Cyclophosphamide can be decreased when combined with Epinastine.]
[C08CA12, mepirodipine, The metabolism of Cyclophosphamide can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Cyclophosphamide can be decreased when combined with Epinephrine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Cyclophosphamide.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be increased when combined with Cyclophosphamide.]
[N03AX15, zonisamide, The metabolism of Cyclophosphamide can be decreased when combined with Zonisamide.]
[N05CF01, zopiclone, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Zopiclone.]
[N05AX11, zotepine, Cyclophosphamide may increase the neurotoxic activities of Zotepine.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Cyclophosphamide.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Carboplatin.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Iloprost is combined with Cyclophosphamide.]
[C01BG01, moricizine, Cyclophosphamide may increase the neurotoxic activities of Moricizine.]
[N02CA02, ergotamine, The metabolism of Cyclophosphamide can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The metabolism of Cyclophosphamide can be decreased when combined with Erythromycin.]
[A02BC02, pantoprazole, The metabolism of Cyclophosphamide can be decreased when combined with Pantoprazole.]
[G03CA03, estradiol, The metabolism of Cyclophosphamide can be decreased when combined with Estradiol.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Estramustine.]
[J04AK02, ethambutol, The metabolism of Cyclophosphamide can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The metabolism of Cyclophosphamide can be increased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Cyclophosphamide can be increased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Cyclophosphamide can be decreased when combined with Fluvastatin.]
[L02AA03, ethinyl estradiol, The metabolism of Cyclophosphamide can be decreased when combined with Ethinylestradiol.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Meloxicam.]
[S01XA06, ethylmorphine, The metabolism of Cyclophosphamide can be decreased when combined with Ethylmorphine.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Etidocaine.]
[L01CB01, etoposide, The metabolism of Etoposide can be increased when combined with Cyclophosphamide.]
[N05AE03, sertindole, Cyclophosphamide may increase the neurotoxic activities of Sertindole.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Cyclophosphamide.]
[R06AX11, astemizole, The metabolism of Astemizole can be increased when combined with Cyclophosphamide.]
[R06AX12, terfenadine, The metabolism of Cyclophosphamide can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The metabolism of Cyclophosphamide can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Cyclophosphamide can be decreased when combined with Fluvoxamine.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Cyclophosphamide.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Dextran is combined with Cyclophosphamide.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cyclophosphamide.]
[P02CA03, albendazole, The metabolism of Cyclophosphamide can be decreased when combined with Albendazole.]
[C08CA02, felodipine, The metabolism of Cyclophosphamide can be decreased when combined with Felodipine.]
[N03AX26, fenfluramine, The metabolism of Cyclophosphamide can be decreased when combined with Fenfluramine.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Cyclophosphamide.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Clofarabine.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Cyclophosphamide.]
[C01BC04, flecainide, The metabolism of Cyclophosphamide can be decreased when combined with Flecainide.]
[J01CF05, floxacillin, The metabolism of Cyclophosphamide can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The metabolism of Cyclophosphamide can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Flucytosine.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Fludrocortisone.]
[N07CA03, flunarizine, The metabolism of Cyclophosphamide can be decreased when combined with Flunarizine.]
[N05CD03, flunitrazepam, The metabolism of Cyclophosphamide can be decreased when combined with Flunitrazepam.]
[D07AC08, fluocinonide, The metabolism of Cyclophosphamide can be increased when combined with Fluocinonide.]
[N06AA14, melitracen, Cyclophosphamide may increase the neurotoxic activities of Melitracen.]
[H02AB03, fluocortolone, The metabolism of Cyclophosphamide can be increased when combined with Fluocortolone.]
[V03AZ01, ethanol, The metabolism of Cyclophosphamide can be increased when combined with Ethanol.]
[L01BC09, floxuridine, The metabolism of Cyclophosphamide can be decreased when combined with Floxuridine.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Cyclophosphamide.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be increased when combined with Cyclophosphamide.]
[N06AB03, fluoxetine, The metabolism of Cyclophosphamide can be decreased when combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Cyclophosphamide.]
[N05AB02, fluphenazine, Cyclophosphamide may increase the neurotoxic activities of Fluphenazine.]
[N05CD01, flurazepam, The metabolism of Cyclophosphamide can be decreased when combined with Flurazepam.]
[S01BC04, flurbiprofen, The metabolism of Flurbiprofen can be decreased when combined with Cyclophosphamide.]
[N05AG01, fluspirilene, Cyclophosphamide may increase the neurotoxic activities of Fluspirilene.]
[L02BB01, flutamide, The metabolism of Cyclophosphamide can be decreased when combined with Flutamide.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Cyclophosphamide.]
[J05AE10, darunavir, The serum concentration of Cyclophosphamide can be increased when it is combined with Darunavir.]
[N05CF04, eszopiclone, The serum concentration of Eszopiclone can be decreased when it is combined with Cyclophosphamide.]
[N05AL05, amisulpride, Cyclophosphamide may increase the neurotoxic activities of Amisulpride.]
[M03AC02, gallamine, Cyclophosphamide may increase the neurotoxic activities of Gallamine.]
[N03AA04, barbexaclone, The metabolism of Cyclophosphamide can be increased when combined with Barbexaclone.]
[C10AB04, gemfibrozil, The metabolism of Cyclophosphamide can be decreased when combined with Gemfibrozil.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be increased when combined with Cyclophosphamide.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be increased when combined with Cyclophosphamide.]
[J05AG04, etravirine, The metabolism of Cyclophosphamide can be increased when combined with Etravirine.]
[N03AD03, methsuximide, The metabolism of Cyclophosphamide can be decreased when combined with Methsuximide.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be increased when combined with Cyclophosphamide.]
[N01AH02, alfentanil, The metabolism of Cyclophosphamide can be decreased when combined with Alfentanil.]
[L01EH01, lapatinib, The metabolism of Cyclophosphamide can be decreased when combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Cyclophosphamide can be decreased when combined with Glyburide.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Cyclophosphamide.]
[A10BB07, glipizide, The metabolism of Glipizide can be decreased when combined with Cyclophosphamide.]
[C05AE01, nitroglycerin, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Nitroglycerin.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be increased when combined with Cyclophosphamide.]
[C02CA04, doxazosin, The metabolism of Cyclophosphamide can be decreased when combined with Doxazosin.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be increased when combined with Cyclophosphamide.]
[B01AA12, fluindione, The therapeutic efficacy of Fluindione can be increased when used in combination with Cyclophosphamide.]
[D01BA01, griseofulvin, The metabolism of Cyclophosphamide can be increased when combined with Griseofulvin.]
[P01BX01, halofantrine, The metabolism of Cyclophosphamide can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Cyclophosphamide.]
[N01AB01, halothane, The metabolism of Cyclophosphamide can be decreased when combined with Halothane.]
[N05AH04, quetiapine, The metabolism of Cyclophosphamide can be decreased when combined with Quetiapine.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be increased when combined with Cyclophosphamide.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Cyclophosphamide.]
[C09CA01, losartan, The metabolism of Cyclophosphamide can be decreased when combined with Losartan.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Cyclophosphamide.]
[G03DC01, allylestrenol, The metabolism of Cyclophosphamide can be decreased when combined with Allylestrenol.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Cyclophosphamide.]
[N05CA16, hexobarbital, The metabolism of Hexobarbital can be decreased when combined with Cyclophosphamide.]
[J05AG01, nevirapine, The metabolism of Cyclophosphamide can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Cyclophosphamide can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of bleeding can be increased when Nimesulide is combined with Cyclophosphamide.]
[C02DB02, hydralazine, The metabolism of Cyclophosphamide can be decreased when combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of granulocytopenia can be increased when Hydrochlorothiazide is combined with Cyclophosphamide.]
[R05DA03, hydrocodone, The metabolism of Cyclophosphamide can be decreased when combined with Hydrocodone.]
[S02BA01, hydrocortisone, The metabolism of Cyclophosphamide can be increased when combined with Hydrocortisone.]
[C03AA02, hydroflumethiazide, The risk or severity of granulocytopenia can be increased when Hydroflumethiazide is combined with Cyclophosphamide.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Hydroxychloroquine.]
[N05AX07, prothipendyl, Cyclophosphamide may increase the neurotoxic activities of Prothipendyl.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Hydroxyurea.]
[N05BB01, hydroxyzine, The metabolism of Cyclophosphamide can be decreased when combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Cyclophosphamide can be increased when combined with Rifabutin.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be increased when combined with Cyclophosphamide.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Cyclophosphamide.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Idarubicin.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be increased when combined with Cyclophosphamide.]
[N06AA02, imipramine, The metabolism of Cyclophosphamide can be decreased when combined with Imipramine.]
[L01CD03, paclitaxel poliglumex, The risk or severity of cardiotoxicity can be increased when Cyclophosphamide is combined with Paclitaxel poliglumex.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be increased when combined with Cyclophosphamide.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Tixocortol.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Topotecan.]
[C03BA11, indapamide, The risk or severity of granulocytopenia can be increased when Indapamide is combined with Cyclophosphamide.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Cyclophosphamide.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Cyclophosphamide.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cyclophosphamide.]
[N06AX17, milnacipran, The metabolism of Milnacipran can be increased when combined with Cyclophosphamide.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Eculizumab.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Articaine.]
[A10BH01, sitagliptin, The metabolism of Sitagliptin can be increased when combined with Cyclophosphamide.]
[N05BA12, alprazolam, The metabolism of Cyclophosphamide can be decreased when combined with Alprazolam.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be decreased when combined with Cyclophosphamide.]
[C10AA06, cerivastatin, The metabolism of Cyclophosphamide can be increased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Anagrelide is combined with Cyclophosphamide.]
[C03BA02, quinethazone, The risk or severity of granulocytopenia can be increased when Quinethazone is combined with Cyclophosphamide.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cyclophosphamide.]
[J05AF04, stavudine, Cyclophosphamide may increase the neurotoxic activities of Stavudine.]
[N06AA13, iprindole, Cyclophosphamide may increase the neurotoxic activities of Iprindole.]
[N06AF05, iproniazid, The metabolism of Cyclophosphamide can be decreased when combined with Iproniazid.]
[N05AA07, chlorproethazine, Cyclophosphamide may increase the neurotoxic activities of Chlorproethazine.]
[P01AX06, atovaquone, The metabolism of Cyclophosphamide can be decreased when combined with Atovaquone.]
[N01AB06, isoflurane, The metabolism of Cyclophosphamide can be decreased when combined with Isoflurane.]
[J04AC01, isoniazid, The metabolism of Cyclophosphamide can be decreased when combined with Isoniazid.]
[C01DA14, isosorbide mononitrate, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Isosorbide dinitrate.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Cyclophosphamide.]
[L04AC07, tocilizumab, The metabolism of Cyclophosphamide can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Cyclophosphamide can be decreased when combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Cyclophosphamide.]
[B01AC22, prasugrel, The metabolism of Cyclophosphamide can be decreased when combined with Prasugrel.]
[H02CA04, levoketoconazole, The metabolism of Cyclophosphamide can be decreased when combined with Levoketoconazole.]
[J02AB02, ketoconazole, The metabolism of Cyclophosphamide can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The metabolism of Cyclophosphamide can be decreased when combined with Olanzapine.]
[M02AA10, ketoprofen, The metabolism of Cyclophosphamide can be decreased when combined with Ketoprofen.]
[V03AC03, deferasirox, The metabolism of Cyclophosphamide can be increased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Cyclophosphamide can be increased when combined with Abatacept.]
[C07AG01, labetalol, The metabolism of Labetalol can be decreased when combined with Cyclophosphamide.]
[N03AX18, lacosamide, The metabolism of Cyclophosphamide can be decreased when combined with Lacosamide.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Cyclophosphamide.]
[G03AD01, levonorgestrel, The metabolism of Cyclophosphamide can be decreased when combined with Levonorgestrel.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Lidocaine.]
[J01FF02, lincomycin, Cyclophosphamide may increase the neurotoxic activities of Lincomycin.]
[N06BA13, armodafinil, The metabolism of Cyclophosphamide can be increased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be increased when combined with Cyclophosphamide.]
[N06AA07, lofepramine, Cyclophosphamide may increase the neurotoxic activities of Lofepramine.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Lomustine.]
[A07DA03, loperamide, The metabolism of Loperamide can be increased when combined with Cyclophosphamide.]
[C10AA02, lovastatin, The metabolism of Cyclophosphamide can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, Loxapine may increase the neurotoxic activities of Cyclophosphamide.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be increased when combined with Cyclophosphamide.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be increased when combined with Cyclophosphamide.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Pralatrexate.]
[L01EA03, nilotinib, The metabolism of Cyclophosphamide can be decreased when combined with Nilotinib.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Mechlorethamine.]
[C01AA08, medigoxin, Metildigoxin may decrease the cardiotoxic activities of Cyclophosphamide.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Cyclophosphamide.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Cyclophosphamide.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Cyclophosphamide.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Melphalan.]
[N06DX01, memantine, The metabolism of Cyclophosphamide can be decreased when combined with Memantine.]
[N02AB02, meperidine, The metabolism of Cyclophosphamide can be decreased when combined with Meperidine.]
[N03AB04, mephenytoin, The metabolism of Cyclophosphamide can be decreased when combined with Mephenytoin.]
[N03AA01, mephobarbital, The metabolism of Cyclophosphamide can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Mepivacaine.]
[L02BG01, aminoglutethimide, The metabolism of Cyclophosphamide can be increased when combined with Aminoglutethimide.]
[N05AC03, mesoridazine, Cyclophosphamide may increase the neurotoxic activities of Mesoridazine.]
[N05AX13, paliperidone, The metabolism of Cyclophosphamide can be decreased when combined with Paliperidone.]
[H01CB03, lanreotide, The metabolism of Cyclophosphamide can be decreased when combined with Lanreotide.]
[N07BC02, methadone, The metabolism of Cyclophosphamide can be decreased when combined with Methadone.]
[H03BB02, methimazole, The metabolism of Cyclophosphamide can be decreased when combined with Methimazole.]
[L03AA02, filgrastim, The risk or severity of pulmonary toxicity can be increased when Filgrastim is combined with Cyclophosphamide.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Pemetrexed.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be increased when combined with Cyclophosphamide.]
[N05AA02, methotrimeprazine, Cyclophosphamide may increase the neurotoxic activities of Methotrimeprazine.]
[D05BA02, methoxsalen, The metabolism of Cyclophosphamide can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The metabolism of Cyclophosphamide can be decreased when combined with Methoxyflurane.]
[C03AA08, methyclothiazide, The risk or severity of granulocytopenia can be increased when Methyclothiazide is combined with Cyclophosphamide.]
[V04CG05, methylene blue, The metabolism of Cyclophosphamide can be decreased when combined with Methylene blue.]
[G02AB01, methylergonovine, The metabolism of Cyclophosphamide can be decreased when combined with Methylergometrine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be increased when combined with Cyclophosphamide.]
[H02AB04, methylprednisolone, The metabolism of Cyclophosphamide can be increased when combined with Methylprednisolone.]
[N03AF03, rufinamide, The metabolism of Cyclophosphamide can be increased when combined with Rufinamide.]
[G03EK01, methyltestosterone, The metabolism of Cyclophosphamide can be decreased when combined with Methyltestosterone.]
[N02CA04, methysergide, The metabolism of Cyclophosphamide can be decreased when combined with Methysergide.]
[A03FA01, metoclopramide, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Metoclopramide.]
[C03BA08, metolazone, The risk or severity of granulocytopenia can be increased when Metolazone is combined with Cyclophosphamide.]
[P01AB01, metronidazole, The metabolism of Cyclophosphamide can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, The metabolism of Cyclophosphamide can be increased when combined with Metyrapone.]
[C01BB02, mexiletine, The metabolism of Cyclophosphamide can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The metabolism of Cyclophosphamide can be decreased when combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Cyclophosphamide can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be increased when combined with Cyclophosphamide.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Cyclophosphamide.]
[N05CD08, midazolam, The metabolism of Cyclophosphamide can be decreased when combined with Midazolam.]
[L03AA09, sargramostim, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Sargramostim.]
[G03XB01, mifepristone, The serum concentration of Cyclophosphamide can be increased when it is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Cyclophosphamide.]
[C09CA03, valsartan, The metabolism of Cyclophosphamide can be decreased when combined with Valsartan.]
[J01FA11, miocamycin, The metabolism of Cyclophosphamide can be decreased when combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Cyclophosphamide can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Mitoxantrone.]
[L03AA03, molgramostim, The risk or severity of pulmonary toxicity can be increased when Molgramostim is combined with Cyclophosphamide.]
[L03AA10, lenograstim, The risk or severity of pulmonary toxicity can be increased when Lenograstim is combined with Cyclophosphamide.]
[N05AE02, molindone, Cyclophosphamide may increase the neurotoxic activities of Molindone.]
[L03AC01, aldesleukin, The metabolism of Cyclophosphamide can be decreased when combined with Aldesleukin.]
[C01BD01, amiodarone, The risk or severity of pulmonary toxicity can be increased when Cyclophosphamide is combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Cyclophosphamide can be decreased when combined with Amitriptyline.]
[N02AA01, morphine, The metabolism of Morphine can be increased when combined with Cyclophosphamide.]
[L04AB05, certolizumab pegol, The metabolism of Cyclophosphamide can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Cyclophosphamide can be decreased when combined with Eltrombopag.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Ofatumumab.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be increased when combined with Cyclophosphamide.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Mycophenolic acid.]
[N05CA02, amobarbital, The metabolism of Cyclophosphamide can be increased when combined with Amobarbital.]
[P01BA06, amodiaquine, The metabolism of Cyclophosphamide can be decreased when combined with Amodiaquine.]
[G03XC01, raloxifene, The metabolism of Cyclophosphamide can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, Cyclophosphamide may increase the neurotoxic activities of Amoxapine.]
[N03AB05, fosphenytoin, The metabolism of Cyclophosphamide can be increased when combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cyclophosphamide.]
[J01CF06, nafcillin, The metabolism of Cyclophosphamide can be increased when combined with Nafcillin.]
[V03AB15, naloxone, The metabolism of Cyclophosphamide can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Cyclophosphamide can be increased when combined with Anakinra.]
[N06BA01, amphetamine, The metabolism of Cyclophosphamide can be decreased when combined with Amphetamine.]
[M02AA12, naproxen, The metabolism of Naproxen can be increased when combined with Cyclophosphamide.]
[A10BG01, troglitazone, The metabolism of Cyclophosphamide can be increased when combined with Troglitazone.]
[N06AX21, duloxetine, The metabolism of Cyclophosphamide can be decreased when combined with Duloxetine.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of pulmonary toxicity can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cyclophosphamide.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be increased when combined with Cyclophosphamide.]
[L02BG04, letrozole, The metabolism of Cyclophosphamide can be decreased when combined with Letrozole.]
[S03AA01, neomycin, Cyclophosphamide may increase the neurotoxic activities of Neomycin.]
[A10BX02, repaglinide, The metabolism of Repaglinide can be increased when combined with Cyclophosphamide.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Cyclophosphamide.]
[N05AX14, iloperidone, The metabolism of Cyclophosphamide can be decreased when combined with Iloperidone.]
[N06AX23, desvenlafaxine, The metabolism of Cyclophosphamide can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, The metabolism of Cyclophosphamide can be decreased when combined with Telmisartan.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Cyclophosphamide.]
[C10AD02, niacin, The metabolism of Cyclophosphamide can be decreased when combined with Niacin.]
[C08CA04, nicardipine, The metabolism of Cyclophosphamide can be decreased when combined with Nicardipine.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Cyclophosphamide.]
[N07BA01, nicotine, The metabolism of Cyclophosphamide can be decreased when combined with Nicotine.]
[C08CA05, nifedipine, The metabolism of Cyclophosphamide can be decreased when combined with Nifedipine.]
[V03AB22, amyl nitrite, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Amyl Nitrite.]
[C08CA07, nisoldipine, The metabolism of Cyclophosphamide can be decreased when combined with Nisoldipine.]
[C08CA08, nitrendipine, The metabolism of Cyclophosphamide can be decreased when combined with Nitrendipine.]
[R07AX01, nitric oxide, The risk or severity of methemoglobinemia can be increased when Nitric Oxide is combined with Cyclophosphamide.]
[J01XE01, nitrofurantoin, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Nitrofurantoin.]
[N05CF03, zaleplon, The metabolism of Cyclophosphamide can be decreased when combined with Zaleplon.]
[C02DD01, nitroprusside, The risk or severity of methemoglobinemia can be increased when Nitroprusside is combined with Cyclophosphamide.]
[N01AX13, nitrous oxide, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Nitrous oxide.]
[G03DC02, norethindrone, The metabolism of Cyclophosphamide can be decreased when combined with Norethisterone.]
[G03AC07, norgestrienone, The metabolism of Norgestrienone can be increased when combined with Cyclophosphamide.]
[C02KX01, bosentan, The metabolism of Cyclophosphamide can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be increased when combined with Cyclophosphamide.]
[R05DA07, noscapine, The metabolism of Cyclophosphamide can be decreased when combined with Noscapine.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Cyclophosphamide.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Cyclophosphamide.]
[H01CB02, octreotide, The serum concentration of Cyclophosphamide can be increased when it is combined with Octreotide.]
[J01FA05, oleandomycin, The metabolism of Cyclophosphamide can be decreased when combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Cyclophosphamide can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Cyclophosphamide can be increased when combined with Omeprazole.]
[N06AA05, opipramol, Cyclophosphamide may increase the neurotoxic activities of Opipramol.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Cyclophosphamide.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Cyclophosphamide.]
[C01AC01, ouabain, Ouabain may decrease the cardiotoxic activities of Cyclophosphamide.]
[A14AA08, oxandrolone, The metabolism of Cyclophosphamide can be decreased when combined with Oxandrolone.]
[N02AA05, oxycodone, The metabolism of Cyclophosphamide can be decreased when combined with Oxycodone.]
[N05AE01, oxypertine, Cyclophosphamide may increase the neurotoxic activities of Oxypertine.]
[J04AA01, aminosalicylic acid, The risk or severity of methemoglobinemia can be increased when Aminosalicylic acid is combined with Cyclophosphamide.]
[N05AH05, asenapine, Cyclophosphamide may increase the neurotoxic activities of Asenapine.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Cyclophosphamide.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be increased when combined with Cyclophosphamide.]
[H02AB05, paramethasone, The metabolism of Cyclophosphamide can be increased when combined with Paramethasone.]
[N05AG03, penfluridol, Cyclophosphamide may increase the neurotoxic activities of Penfluridol.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Penicillamine.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclophosphamide.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclophosphamide.]
[N05CA01, pentobarbital, The metabolism of Cyclophosphamide can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Pentostatin may increase the cardiotoxic activities of Cyclophosphamide.]
[C04AD03, pentoxifylline, The risk or severity of bleeding can be increased when Pentoxifylline is combined with Cyclophosphamide.]
[N05AB10, perazine, Cyclophosphamide may increase the neurotoxic activities of Perazine.]
[C08EX02, perhexiline, The metabolism of Cyclophosphamide can be decreased when combined with Perhexiline.]
[B02BX04, romiplostim, The risk or severity of pulmonary toxicity can be increased when Romiplostim is combined with Cyclophosphamide.]
[N05AB03, perphenazine, Cyclophosphamide may increase the neurotoxic activities of Perphenazine.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Cyclophosphamide.]
[N02BE03, phenacetin, The metabolism of Cyclophosphamide can be decreased when combined with Phenacetin.]
[G04BX06, phenazopyridine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Phenazopyridine.]
[B01AA02, phenindione, The therapeutic efficacy of Phenindione can be increased when used in combination with Cyclophosphamide.]
[N03AA02, phenobarbital, The metabolism of Cyclophosphamide can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Cyclophosphamide.]
[M02AA01, phenylbutazone, The metabolism of Cyclophosphamide can be increased when combined with Phenylbutazone.]
[A02BC06, dexlansoprazole, The metabolism of Cyclophosphamide can be decreased when combined with Dexlansoprazole.]
[N03AB02, phenytoin, The metabolism of Cyclophosphamide can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Cyclophosphamide can be increased when combined with Golimumab.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be increased when combined with Cyclophosphamide.]
[C08CX01, mibefradil, The metabolism of Cyclophosphamide can be decreased when combined with Mibefradil.]
[S01EB01, pilocarpine, The metabolism of Cyclophosphamide can be decreased when combined with Pilocarpine.]
[N05AG02, pimozide, The metabolism of Pimozide can be increased when combined with Cyclophosphamide.]
[C10AA05, atorvastatin, The metabolism of Cyclophosphamide can be decreased when combined with Atorvastatin.]
[J05AE01, saquinavir, The serum concentration of the active metabolites of Cyclophosphamide can be increased when Cyclophosphamide is used in combination with Saquinavir.]
[N05AC04, pipothiazine, Cyclophosphamide may increase the neurotoxic activities of Pipotiazine.]
[S01BC06, piroxicam, The metabolism of Piroxicam can be increased when combined with Cyclophosphamide.]
[J05AG02, delavirdine, The metabolism of Cyclophosphamide can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Cyclophosphamide can be decreased when combined with Irbesartan.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Cyclophosphamide.]
[D05AX05, tazarotene, The metabolism of Tazarotene can be increased when combined with Cyclophosphamide.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Cyclophosphamide.]
[A10BG02, rosiglitazone, The metabolism of Rosiglitazone can be increased when combined with Cyclophosphamide.]
[L02BG03, anastrozole, The risk or severity of cardiotoxicity can be increased when Cyclophosphamide is combined with Anastrozole.]
[A03AE01, alosetron, The metabolism of Alosetron can be decreased when combined with Cyclophosphamide.]
[L04AC08, canakinumab, The metabolism of Cyclophosphamide can be increased when combined with Canakinumab.]
[S03AA03, polymyxin B, Cyclophosphamide may increase the neurotoxic activities of Polymyxin B.]
[C03AA05, polythiazide, The risk or severity of granulocytopenia can be increased when Polythiazide is combined with Cyclophosphamide.]
[J05AE03, ritonavir, The serum concentration of the active metabolites of Cyclophosphamide can be increased when Cyclophosphamide is used in combination with Ritonavir.]
[A10BH03, saxagliptin, The metabolism of Cyclophosphamide can be decreased when combined with Saxagliptin.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be increased when combined with Cyclophosphamide.]
[P02BA01, praziquantel, The metabolism of Cyclophosphamide can be decreased when combined with Praziquantel.]
[S03BA02, prednisolone, The metabolism of Cyclophosphamide can be increased when combined with Prednisolone.]
[H02AB07, prednisone, The metabolism of Cyclophosphamide can be increased when combined with Prednisone.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Cyclophosphamide can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Cyclophosphamide can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Cyclophosphamide can be increased when combined with Probenecid.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Procarbazine.]
[C10AB05, fenofibrate, The metabolism of Cyclophosphamide can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, Prochlorperazine may increase the neurotoxic activities of Cyclophosphamide.]
[G03DA04, progesterone, The metabolism of Cyclophosphamide can be decreased when combined with Progesterone.]
[N05AA03, promazine, The metabolism of Cyclophosphamide can be decreased when combined with Promazine.]
[R06AD02, promethazine, The metabolism of Cyclophosphamide can be decreased when combined with Promethazine.]
[N05AC01, periciazine, Cyclophosphamide may increase the neurotoxic activities of Periciazine.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be increased when combined with Cyclophosphamide.]
[N01AX10, propofol, The metabolism of Cyclophosphamide can be decreased when combined with Propofol.]
[N02AC04, propoxyphene, The metabolism of Cyclophosphamide can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, The metabolism of Cyclophosphamide can be decreased when combined with Propranolol.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Propylthiouracil.]
[C01AB01, proscillaridin, Proscillaridin may decrease the cardiotoxic activities of Cyclophosphamide.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Cyclophosphamide.]
[R03DC03, montelukast, The metabolism of Cyclophosphamide can be decreased when combined with Montelukast.]
[N06AA11, protriptyline, Protriptyline may increase the neurotoxic activities of Cyclophosphamide.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be increased when combined with Cyclophosphamide.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Cyclophosphamide.]
[P01BD01, pyrimethamine, The metabolism of Cyclophosphamide can be decreased when combined with Pyrimethamine.]
[P01AX05, quinacrine, The metabolism of Cyclophosphamide can be decreased when combined with Quinacrine.]
[C01BA01, quinidine, The metabolism of Quinidine can be increased when combined with Cyclophosphamide.]
[P01BC01, quinine, The metabolism of Cyclophosphamide can be increased when combined with Quinine.]
[C02AA02, reserpine, The metabolism of Cyclophosphamide can be increased when combined with Reserpine.]
[J04AB02, rifampin, The metabolism of Cyclophosphamide can be increased when combined with Rifampicin.]
[J01FA06, roxithromycin, The metabolism of Cyclophosphamide can be decreased when combined with Roxithromycin.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The metabolism of Salicylic acid can be decreased when combined with Cyclophosphamide.]
[N05CA06, secobarbital, The metabolism of Cyclophosphamide can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The metabolism of Cyclophosphamide can be decreased when combined with Selegiline.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Cyclophosphamide.]
[H01CB01, somatostatin, The metabolism of Cyclophosphamide can be decreased when combined with Somatostatin.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be increased when combined with Cyclophosphamide.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cyclophosphamide.]
[C03DA01, spironolactone, The metabolism of Cyclophosphamide can be decreased when combined with Spironolactone.]
[N03AG01, valproic acid, The metabolism of Cyclophosphamide can be decreased when combined with Valproic acid.]
[D07AB02, hydrocortisone butyrate, The metabolism of Cyclophosphamide can be increased when combined with Hydrocortisone butyrate.]
[S02DA03, antipyrine, The metabolism of Cyclophosphamide can be decreased when combined with Antipyrine.]
[G03XB02, ulipristal, The metabolism of Ulipristal can be increased when combined with Cyclophosphamide.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Cyclophosphamide.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cyclophosphamide.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Cyclophosphamide.]
[L04AA27, fingolimod, Cyclophosphamide may increase the immunosuppressive activities of Fingolimod.]
[M03AB01, succinylcholine, The serum concentration of Succinylcholine can be increased when it is combined with Cyclophosphamide.]
[J01EC02, sulfadiazine, The metabolism of Cyclophosphamide can be decreased when combined with Sulfadiazine.]
[S01AB01, sulfamethizole, The metabolism of Cyclophosphamide can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Cyclophosphamide.]
[J01EC03, sulfamoxole, The metabolism of Cyclophosphamide can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The metabolism of Cyclophosphamide can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Cyclophosphamide can be increased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The metabolism of Cyclophosphamide can be decreased when combined with Sulfisoxazole.]
[N05AL01, sulpiride, Sulpiride may increase the neurotoxic activities of Cyclophosphamide.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be decreased when combined with Cyclophosphamide.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Mercaptopurine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be increased when combined with Cyclophosphamide.]
[L01CB02, teniposide, The metabolism of Teniposide can be increased when combined with Cyclophosphamide.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Cyclophosphamide.]
[G03BA03, testosterone, The metabolism of Cyclophosphamide can be increased when combined with Testosterone.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Tetracaine.]
[S03AA02, tetracycline, The metabolism of Cyclophosphamide can be decreased when combined with Tetracycline.]
[N05AE05, lurasidone, Cyclophosphamide may increase the neurotoxic activities of Lurasidone.]
[A04AD10, dronabinol, The metabolism of Cyclophosphamide can be decreased when combined with Dronabinol.]
[N04BC07, apomorphine, The metabolism of Cyclophosphamide can be decreased when combined with Apomorphine.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Thalidomide.]
[R03DA04, theophylline, The metabolism of Theophylline can be increased when combined with Cyclophosphamide.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Eribulin.]
[R06AD03, thiethylperazine, Thiethylperazine may increase the neurotoxic activities of Cyclophosphamide.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be increased when combined with Cyclophosphamide.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Cyclophosphamide.]
[N05CA19, thiopental, The metabolism of Thiopental can be decreased when combined with Cyclophosphamide.]
[N05AB08, thioproperazine, Cyclophosphamide may increase the neurotoxic activities of Thioproperazine.]
[N05AC02, thioridazine, The metabolism of Thioridazine can be decreased when combined with Cyclophosphamide.]
[N05AF04, thiothixene, Cyclophosphamide may increase the neurotoxic activities of Thiothixene.]
[N05AL03, tiapride, Cyclophosphamide may increase the neurotoxic activities of Tiapride.]
[B01AC05, ticlopidine, The metabolism of Cyclophosphamide can be decreased when combined with Ticlopidine.]
[S01ED01, timolol, The metabolism of Cyclophosphamide can be decreased when combined with Timolol.]
[A10BB05, tolazamide, The metabolism of Tolazamide can be decreased when combined with Cyclophosphamide.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be increased when combined with Cyclophosphamide.]
[N02AX02, tramadol, The metabolism of Tramadol can be increased when combined with Cyclophosphamide.]
[N06AF04, tranylcypromine, The metabolism of Cyclophosphamide can be decreased when combined with Tranylcypromine.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Cyclophosphamide.]
[N06AX05, trazodone, The metabolism of Cyclophosphamide can be decreased when combined with Trazodone.]
[L01XF01, tretinoin, The metabolism of Cyclophosphamide can be decreased when combined with Tretinoin.]
[S01BA05, triamcinolone, The metabolism of Cyclophosphamide can be increased when combined with Triamcinolone.]
[N05CD05, triazolam, The metabolism of Cyclophosphamide can be decreased when combined with Triazolam.]
[C03AA06, trichlormethiazide, The risk or severity of granulocytopenia can be increased when Trichlormethiazide is combined with Cyclophosphamide.]
[N05AB06, trifluoperazine, Cyclophosphamide may increase the neurotoxic activities of Trifluoperazine.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Cyclophosphamide.]
[N05AD02, trifluperidol, Cyclophosphamide may increase the neurotoxic activities of Trifluperidol.]
[N05AA05, triflupromazine, Triflupromazine may increase the neurotoxic activities of Cyclophosphamide.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Fluclorolone.]
[R03BA07, mometasone, The metabolism of Cyclophosphamide can be increased when combined with Mometasone.]
[R06AD01, trimeprazine, Cyclophosphamide may increase the neurotoxic activities of Alimemazine.]
[N03AC02, trimethadione, The metabolism of Trimethadione can be increased when combined with Cyclophosphamide.]
[J01EA01, trimethoprim, The metabolism of Cyclophosphamide can be decreased when combined with Trimethoprim.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Cyclophosphamide.]
[J01FA08, troleandomycin, The metabolism of Cyclophosphamide can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Vilazodone can be decreased when combined with Cyclophosphamide.]
[M03AA02, tubocurarine, Cyclophosphamide may increase the neurotoxic activities of Tubocurarine.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Cyclophosphamide.]
[L04AA26, belimumab, The risk or severity of leukopenia can be increased when Belimumab is combined with Cyclophosphamide.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be increased when combined with Cyclophosphamide.]
[L02BX03, abiraterone, The metabolism of Cyclophosphamide can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Cyclophosphamide can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Cyclophosphamide can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Cyclophosphamide can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Cyclophosphamide.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Cyclophosphamide.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Belatacept.]
[B01AF01, rivaroxaban, The metabolism of Cyclophosphamide can be decreased when combined with Rivaroxaban.]
[B01AC24, ticagrelor, The metabolism of Cyclophosphamide can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Cyclophosphamide can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Cyclophosphamide can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be increased when combined with Cyclophosphamide.]
[L01CA02, vincristine, The metabolism of Vincristine can be increased when combined with Cyclophosphamide.]
[L01CA03, vindesine, The metabolism of Vindesine can be increased when combined with Cyclophosphamide.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cyclophosphamide.]
[A11HA03, vitamin E, The metabolism of Cyclophosphamide can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The therapeutic efficacy of Warfarin can be increased when used in combination with Cyclophosphamide.]
[J05AF01, zidovudine, The metabolism of Cyclophosphamide can be decreased when combined with Zidovudine.]
[N05AF05, zuclopenthixol, The metabolism of Cyclophosphamide can be decreased when combined with Zuclopenthixol.]
[J05AE02, indinavir, The serum concentration of the active metabolites of Cyclophosphamide can be increased when Cyclophosphamide is used in combination with Indinavir.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be increased when combined with Cyclophosphamide.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be increased when combined with Cyclophosphamide.]
[L01ED01, crizotinib, The metabolism of Cyclophosphamide can be decreased when combined with Crizotinib.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Cyclophosphamide.]
[R03DC01, zafirlukast, The metabolism of Cyclophosphamide can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, The metabolism of Cyclophosphamide can be decreased when combined with Rabeprazole.]
[N05AE04, ziprasidone, The metabolism of Cyclophosphamide can be decreased when combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Cyclophosphamide can be decreased when combined with Drospirenone.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cyclophosphamide.]
[N02BA01, aspirin, The metabolism of Cyclophosphamide can be increased when combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be increased when combined with Cyclophosphamide.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be decreased when combined with Cyclophosphamide.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cyclophosphamide.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Cyclophosphamide.]
[J02AC03, voriconazole, The metabolism of Cyclophosphamide can be decreased when combined with Voriconazole.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Cyclophosphamide.]
[L01EK01, axitinib, The metabolism of Axitinib can be increased when combined with Cyclophosphamide.]
[R07AX02, ivacaftor, The metabolism of Cyclophosphamide can be decreased when combined with Ivacaftor.]
[H02AB11, prednylidene, The metabolism of Cyclophosphamide can be increased when combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Cyclophosphamide.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Azacitidine.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Cyclophosphamide.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Cyclophosphamide.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Cyclophosphamide.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Cyclophosphamide.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cyclophosphamide.]
[L01FD02, pertuzumab, The risk or severity of cardiotoxicity can be increased when Cyclophosphamide is combined with Pertuzumab.]
[A08AA11, lorcaserin, The metabolism of Cyclophosphamide can be decreased when combined with Lorcaserin.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Carfilzomib.]
[V03AX03, cobicistat, The metabolism of Cyclophosphamide can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Cyclophosphamide can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Cyclophosphamide can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be increased when combined with Cyclophosphamide.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Cyclophosphamide.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Aldosterone.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be increased when combined with Cyclophosphamide.]
[N05CA04, barbital, The metabolism of Cyclophosphamide can be increased when combined with Barbital.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may decrease the cardiotoxic activities of Cyclophosphamide.]
[J05AE04, nelfinavir, The serum concentration of the active metabolites of Cyclophosphamide can be increased when Cyclophosphamide is used in combination with Nelfinavir.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Bendamustine.]
[C08CA13, lercanidipine, The metabolism of Cyclophosphamide can be decreased when combined with Lercanidipine.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Cyclophosphamide.]
[N03AX22, perampanel, The metabolism of Perampanel can be increased when combined with Cyclophosphamide.]
[L04AA29, tofacitinib, Cyclophosphamide may increase the immunosuppressive activities of Tofacitinib.]
[N01AA01, ethyl ether, Cyclophosphamide may increase the neurotoxic activities of Diethyl ether.]
[L01EX07, cabozantinib, The metabolism of Cyclophosphamide can be decreased when combined with Cabozantinib.]
[H01CB05, pasireotide, The metabolism of Cyclophosphamide can be decreased when combined with Pasireotide.]
[G04BE03, sildenafil, The metabolism of Cyclophosphamide can be decreased when combined with Sildenafil.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be increased when combined with Cyclophosphamide.]
[B01AF02, apixaban, The metabolism of Cyclophosphamide can be decreased when combined with Apixaban.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be increased when combined with Cyclophosphamide.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Cyclophosphamide can be increased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The risk or severity of granulocytopenia can be increased when Bendroflumethiazide is combined with Cyclophosphamide.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be increased when combined with Cyclophosphamide.]
[G03XC05, ospemifene, The metabolism of Cyclophosphamide can be decreased when combined with Ospemifene.]
[N05AD07, benperidol, Cyclophosphamide may increase the neurotoxic activities of Benperidol.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Dimethyl fumarate.]
[M04AB03, benzbromarone, The metabolism of Cyclophosphamide can be decreased when combined with Benzbromarone.]
[A06AX06, tegaserod, The metabolism of Cyclophosphamide can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Benzocaine.]
[L03AA12, ancestim, The risk or severity of pulmonary toxicity can be increased when Ancestim is combined with Cyclophosphamide.]
[M01AH01, celecoxib, The risk or severity of methemoglobinemia can be increased when Celecoxib is combined with Cyclophosphamide.]
[L04AA18, everolimus, The metabolism of Everolimus can be increased when combined with Cyclophosphamide.]
[L01EC02, dabrafenib, The serum concentration of Cyclophosphamide can be decreased when it is combined with Dabrafenib.]
[L01EE01, trametinib, The metabolism of Cyclophosphamide can be decreased when combined with Trametinib.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be increased when combined with Cyclophosphamide.]
[C02KX05, riociguat, The metabolism of Riociguat can be increased when combined with Cyclophosphamide.]
[L03AA14, lipegfilgrastim, Cyclophosphamide may increase the myelosuppressive activities of Lipegfilgrastim.]
[L01EL01, ibrutinib, The metabolism of Cyclophosphamide can be decreased when combined with Ibrutinib.]
[N06AX26, vortioxetine, The metabolism of Cyclophosphamide can be decreased when combined with Vortioxetine.]
[G03AC08, etonogestrel, The metabolism of Etonogestrel can be increased when combined with Cyclophosphamide.]
[N03AF04, eslicarbazepine, The metabolism of Cyclophosphamide can be increased when combined with Eslicarbazepine.]
[D01AC18, luliconazole, The serum concentration of Cyclophosphamide can be increased when it is combined with Luliconazole.]
[J05AP05, simeprevir, The metabolism of Cyclophosphamide can be decreased when combined with Simeprevir.]
[A10BK01, dapagliflozin, The metabolism of Cyclophosphamide can be decreased when combined with Dapagliflozin.]
[N05CH03, tasimelteon, The metabolism of Cyclophosphamide can be decreased when combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Cyclophosphamide can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Cyclophosphamide can be increased when combined with Apremilast.]
[L02BG02, formestane, The metabolism of Cyclophosphamide can be increased when combined with Formestane.]
[S03BA03, betamethasone, The metabolism of Cyclophosphamide can be increased when combined with Betamethasone.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Cyclophosphamide.]
[V03AB34, fomepizole, The metabolism of Cyclophosphamide can be decreased when combined with Fomepizole.]
[C10AB02, bezafibrate, The metabolism of Cyclophosphamide can be decreased when combined with Bezafibrate.]
[L04AC11, siltuximab, The metabolism of Cyclophosphamide can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be increased when combined with Cyclophosphamide.]
[B01AC26, vorapaxar, The metabolism of Cyclophosphamide can be decreased when combined with Vorapaxar.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Vedolizumab.]
[B01AA07, acenocoumarol, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Cyclophosphamide.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Belinostat.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be increased when combined with Cyclophosphamide.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be increased when combined with Cyclophosphamide.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Peginterferon beta-1a.]
[N05CM19, suvorexant, The metabolism of Cyclophosphamide can be decreased when combined with Suvorexant.]
[J01XA05, oritavancin, The metabolism of Cyclophosphamide can be increased when combined with Oritavancin.]
[N05AA04, acepromazine, Cyclophosphamide may increase the neurotoxic activities of Acepromazine.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Decitabine.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Pirfenidone.]
[L01EX09, nintedanib, The metabolism of Cyclophosphamide can be decreased when combined with Nintedanib.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Blinatumomab.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be increased when combined with Cyclophosphamide.]
[L01XK01, olaparib, The metabolism of Olaparib can be increased when combined with Cyclophosphamide.]
[B01AA01, dicumarol, The therapeutic efficacy of Dicoumarol can be increased when used in combination with Cyclophosphamide.]
[B01AF03, edoxaban, The risk or severity of bleeding can be increased when Edoxaban is combined with Cyclophosphamide.]
[N06AX11, mirtazapine, The metabolism of Cyclophosphamide can be decreased when combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Cyclophosphamide can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be increased when combined with Cyclophosphamide.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be increased when combined with Cyclophosphamide.]
[J05AP07, daclatasvir, The metabolism of Cyclophosphamide can be decreased when combined with Daclatasvir.]
[N02BE01, acetaminophen, The metabolism of Cyclophosphamide can be increased when combined with Acetaminophen.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Cyclophosphamide.]
[B01AA11, tioclomarol, The therapeutic efficacy of Tioclomarol can be increased when used in combination with Cyclophosphamide.]
[J05AP06, asunaprevir, The serum concentration of the active metabolites of Cyclophosphamide can be increased when Cyclophosphamide is used in combination with Asunaprevir.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Cyclophosphamide.]
[N05AX16, brexpiprazole, Cyclophosphamide may increase the neurotoxic activities of Brexpiprazole.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be increased when combined with Cyclophosphamide.]
[N05AX15, cariprazine, Cyclophosphamide may increase the neurotoxic activities of Cariprazine.]
[S01EC01, acetazolamide, The metabolism of Cyclophosphamide can be decreased when combined with Acetazolamide.]
[N05AB07, acetophenazine, Cyclophosphamide may increase the neurotoxic activities of Acetophenazine.]
[A02BC03, lansoprazole, The metabolism of Cyclophosphamide can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be increased when combined with Cyclophosphamide.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Mepolizumab.]
[J02AC05, isavuconazole, The metabolism of Cyclophosphamide can be increased when combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be increased when combined with Cyclophosphamide.]
[J05AF13, tenofovir alafenamide, The metabolism of Cyclophosphamide can be decreased when combined with Tenofovir alafenamide.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be increased when combined with Cyclophosphamide.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be increased when combined with Cyclophosphamide.]
[L01ED03, alectinib, The metabolism of Alectinib can be increased when combined with Cyclophosphamide.]
[B01AC27, selexipag, The metabolism of Selexipag can be increased when combined with Cyclophosphamide.]
[A10BB31, acetohexamide, The metabolism of Cyclophosphamide can be decreased when combined with Acetohexamide.]
[M04AB05, lesinurad, The metabolism of Cyclophosphamide can be increased when combined with Lesinurad.]
[J05AP10, elbasvir, The metabolism of Cyclophosphamide can be decreased when combined with Elbasvir.]
[N05CA05, aprobarbital, The metabolism of Cyclophosphamide can be increased when combined with Aprobarbital.]
[N03AX23, brivaracetam, The metabolism of Cyclophosphamide can be decreased when combined with Brivaracetam.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Ixekizumab.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be increased when combined with Cyclophosphamide.]
[R06AB01, brompheniramine, The metabolism of Cyclophosphamide can be decreased when combined with Brompheniramine.]
[N06AA19, amineptin, Cyclophosphamide may increase the neurotoxic activities of Amineptine.]
[C08CA01, amlodipine, The metabolism of Amlodipine can be increased when combined with Cyclophosphamide.]
[N05AX17, pimavanserin, The metabolism of Cyclophosphamide can be decreased when combined with Pimavanserin.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Bupivacaine.]
[N07BC01, buprenorphine, The metabolism of Cyclophosphamide can be decreased when combined with Buprenorphine.]
[N05BE01, buspirone, The metabolism of Cyclophosphamide can be decreased when combined with Buspirone.]
[L01AB01, busulfan, The metabolism of Busulfan can be increased when combined with Cyclophosphamide.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Arsenic trioxide.]
[P01BE02, artemether, The metabolism of Cyclophosphamide can be decreased when combined with Artemether.]
[M02AA03, clofezone, The metabolism of Cyclophosphamide can be decreased when combined with Rabeprazole.]
[S01GX07, azelastine, The metabolism of Cyclophosphamide can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Cyclophosphamide can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The metabolism of Cyclophosphamide can be decreased when combined with Azithromycin.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Brodalumab.]
[L01EF02, ribociclib, The metabolism of Cyclophosphamide can be decreased when combined with Ribociclib.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Cyclophosphamide.]
[N07XX16, deutetrabenazine, The metabolism of Cyclophosphamide can be decreased when combined with Deutetrabenazine.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Oxybuprocaine.]
[D05AX03, calcitriol, The metabolism of Cyclophosphamide can be increased when combined with Calcitriol.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Cyclophosphamide.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Linezolid.]
[J05AE09, tipranavir, The serum concentration of the active metabolites of Cyclophosphamide can be increased when Cyclophosphamide is used in combination with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Cyclophosphamide can be decreased when combined with Valbenazine.]
[L04AB02, infliximab, The metabolism of Cyclophosphamide can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Cyclophosphamide can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be increased when combined with Cyclophosphamide.]
[L04AC14, sarilumab, The metabolism of Cyclophosphamide can be increased when combined with Sarilumab.]
[J01MA23, delafloxacin, The metabolism of Cyclophosphamide can be increased when combined with Delafloxacin.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Cyclophosphamide.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Guselkumab.]
[D01AC10, bifonazole, The metabolism of Cyclophosphamide can be decreased when combined with Bifonazole.]
[L01BC06, capecitabine, The metabolism of Cyclophosphamide can be decreased when combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be increased when combined with Cyclophosphamide.]
[L01EH02, neratinib, The metabolism of Neratinib can be increased when combined with Cyclophosphamide.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Vorinostat.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be increased when combined with Cyclophosphamide.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be increased when combined with Cyclophosphamide.]
[A02BX12, bismuth subnitrate, Cyclophosphamide may increase the neurotoxic activities of Bismuth subnitrate.]
[J05AG03, efavirenz, The metabolism of Cyclophosphamide can be decreased when combined with Efavirenz.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Cyclophosphamide.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Cyclophosphamide.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Cyclophosphamide.]
[N05AD06, bromperidol, Cyclophosphamide may increase the neurotoxic activities of Bromperidol.]
[R03BA02, budesonide, The metabolism of Cyclophosphamide can be increased when combined with Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Cyclophosphamide.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be increased when combined with Cyclophosphamide.]
[J05AX18, letermovir, The metabolism of Cyclophosphamide can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, Cyclophosphamide may increase the neurotoxic activities of Butriptyline.]
[C01AA02, acetyldigoxins, Acetyldigoxin may decrease the cardiotoxic activities of Cyclophosphamide.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Capsaicin.]
[L02BB05, apalutamide, The serum concentration of Cyclophosphamide can be increased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Cyclophosphamide can be increased when combined with Carbamazepine.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Cyclophosphamide.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be decreased when combined with Cyclophosphamide.]
[B02BX09, fostamatinib, The metabolism of Cyclophosphamide can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The metabolism of Cyclophosphamide can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The metabolism of Cyclophosphamide can be increased when combined with Avatrombopag.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Baricitinib.]
[H01CC03, elagolix, The metabolism of Elagolix can be increased when combined with Cyclophosphamide.]
[L01XX62, ivosidenib, The metabolism of Cyclophosphamide can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Cyclophosphamide can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Cyclophosphamide can be increased when combined with Tecovirimat.]
[J05AG06, doravirine, The metabolism of Cyclophosphamide can be decreased when combined with Doravirine.]
[L01EM04, duvelisib, The metabolism of Cyclophosphamide can be decreased when combined with Duvelisib.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be increased when combined with Cyclophosphamide.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Cyclophosphamide.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Chloroprocaine.]
[M01AC05, lornoxicam, The metabolism of Lornoxicam can be decreased when combined with Cyclophosphamide.]
[M03BA02, carisoprodol, The metabolism of Cyclophosphamide can be decreased when combined with Carisoprodol.]
[L01ED05, lorlatinib, The metabolism of Cyclophosphamide can be increased when combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Cyclophosphamide can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Cyclophosphamide.]
[L01EX13, gilteritinib, The metabolism of Cyclophosphamide can be decreased when combined with Gilteritinib.]
[L01XJ03, glasdegib, The metabolism of Glasdegib can be increased when combined with Cyclophosphamide.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Ravulizumab.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Cyclophosphamide.]
[B01AC23, cilostazol, The metabolism of Cyclophosphamide can be decreased when combined with Cilostazol.]
[P02BX04, triclabendazole, The metabolism of Cyclophosphamide can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The metabolism of Cyclophosphamide can be increased when combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Siponimod can be increased when combined with Cyclophosphamide.]
[J01FA09, clarithromycin, The metabolism of Cyclophosphamide can be decreased when combined with Clarithromycin.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be increased when combined with Cyclophosphamide.]
[N05BA09, clobazam, The metabolism of Cyclophosphamide can be increased when combined with Clobazam.]
[H02AB14, cloprednol, The metabolism of Cyclophosphamide can be increased when combined with Cloprednol.]
[C09CA06, candesartan, The metabolism of Cyclophosphamide can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Cyclophosphamide.]
[H02AB17, cortivazol, The metabolism of Cyclophosphamide can be increased when combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Risankizumab.]
[L01EM03, alpelisib, The serum concentration of Cyclophosphamide can be decreased when it is combined with Alpelisib.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be increased when combined with Cyclophosphamide.]
[N05AA06, cyamemazine, Cyclophosphamide may increase the neurotoxic activities of Cyamemazine.]
[M03BX08, cyclobenzaprine, Cyclophosphamide may increase the neurotoxic activities of Cyclobenzaprine.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Upadacitinib.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Cyclophosphamide.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be increased when combined with Cyclophosphamide.]
[N07XX11, pitolisant, The serum concentration of Cyclophosphamide can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Cyclophosphamide can be decreased when combined with Pretomanid.]
[J01XX12, lefamulin, The serum concentration of Cyclophosphamide can be increased when it is combined with Lefamulin.]
[N04CX01, istradefylline, The metabolism of Cyclophosphamide can be decreased when combined with Istradefylline.]
[C03AA09, cyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Cyclophosphamide.]
[J01DB01, cephalexin, The metabolism of Cyclophosphamide can be decreased when combined with Cephalexin.]
[J01DB09, cephradine, The metabolism of Cyclophosphamide can be increased when combined with Cefradine.]
[H02AB13, deflazacort, The metabolism of Cyclophosphamide can be increased when combined with Deflazacort.]
[G03DB05, demegestone, The metabolism of Demegestone can be increased when combined with Cyclophosphamide.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Cyclophosphamide.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be increased when combined with Cyclophosphamide.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Diroximel fumarate.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be increased when combined with Cyclophosphamide.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be increased when combined with Cyclophosphamide.]
[B06AX03, voxelotor, The serum concentration of Cyclophosphamide can be increased when it is combined with Voxelotor.]
[N03AX25, cenobamate, The serum concentration of Cyclophosphamide can be decreased when it is combined with Cenobamate.]
[L01EX18, avapritinib, The metabolism of Cyclophosphamide can be decreased when combined with Avapritinib.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be decreased when it is combined with Cyclophosphamide.]
[L01XX72, tazemetostat, The metabolism of Cyclophosphamide can be decreased when combined with Tazemetostat.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Teprotumumab.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be decreased when it is combined with Cyclophosphamide.]
[M01AX21, diacetylrhein, The metabolism of Cyclophosphamide can be decreased when combined with Diacerein.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be increased when combined with Cyclophosphamide.]
[J05AB16, remdesivir, The metabolism of Cyclophosphamide can be decreased when combined with Remdesivir.]
[H02CA02, osilodrostat, The serum concentration of Cyclophosphamide can be increased when it is combined with Osilodrostat.]
[J05AE05, amprenavir, The serum concentration of the active metabolites of Cyclophosphamide can be increased when Cyclophosphamide is used in combination with Amprenavir.]
[G04CB02, dutasteride, The metabolism of Cyclophosphamide can be decreased when combined with Dutasteride.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Ozanimod.]
[L01EE04, selumetinib, The metabolism of Cyclophosphamide can be decreased when combined with Selumetinib.]
[G03DB08, dienogest, The metabolism of Dienogest can be increased when combined with Cyclophosphamide.]
[N02CC06, eletriptan, The metabolism of Cyclophosphamide can be increased when combined with Eletriptan.]
[M01AH02, rofecoxib, The metabolism of Cyclophosphamide can be increased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Cyclophosphamide can be increased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Cyclophosphamide can be increased when combined with Clevidipine.]
[C01BD07, dronedarone, The serum concentration of Cyclophosphamide can be increased when it is combined with Dronedarone.]
[J01FA13, dirithromycin, The metabolism of Cyclophosphamide can be decreased when combined with Dirithromycin.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Cyclophosphamide.]
[S03AA08, chloramphenicol, The metabolism of Cyclophosphamide can be decreased when combined with Chloramphenicol.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Cyclophosphamide.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be decreased when it is combined with Cyclophosphamide.]
[D07XB03, fluprednidene, The metabolism of Cyclophosphamide can be increased when combined with Fluprednidene.]
[P01BE01, artemisinin, The metabolism of Cyclophosphamide can be decreased when combined with Artemisinin.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Cyclophosphamide.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Cyclophosphamide.]
[N05CM02, chlormethiazole, The metabolism of Cyclophosphamide can be decreased when combined with Clomethiazole.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Cyclophosphamide is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Stepronin.]
[C08CA17, levamlodipine, The metabolism of Cyclophosphamide can be decreased when combined with Levamlodipine.]
[R06AX22, ebastine, The metabolism of Cyclophosphamide can be decreased when combined with Ebastine.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Cyclophosphamide.]
[L04AC19, satralizumab, The serum concentration of Cyclophosphamide can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The serum concentration of Oliceridine can be decreased when it is combined with Cyclophosphamide.]
[P01BA01, chloroquine, The metabolism of Cyclophosphamide can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The metabolism of Cyclophosphamide can be increased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The risk or severity of granulocytopenia can be increased when Chlorothiazide is combined with Cyclophosphamide.]
[R06AB04, chlorpheniramine, The metabolism of Cyclophosphamide can be decreased when combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Cyclophosphamide can be increased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The metabolism of Chlorpropamide can be decreased when combined with Cyclophosphamide.]
[N05AF03, chlorprothixene, Cyclophosphamide may increase the neurotoxic activities of Chlorprothixene.]
[C03BA04, chlorthalidone, The risk or severity of granulocytopenia can be increased when Chlorthalidone is combined with Cyclophosphamide.]
[M03BB03, chlorzoxazone, The metabolism of Cyclophosphamide can be decreased when combined with Chlorzoxazone.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be increased when combined with Cyclophosphamide.]
[M01AB08, etodolac, The metabolism of Etodolac can be decreased when combined with Cyclophosphamide.]
[B06AC06, berotralstat, The serum concentration of Cyclophosphamide can be increased when it is combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Cyclophosphamide can be decreased when combined with Lonafarnib.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Fludarabine.]
[L02BX04, relugolix, The metabolism of Cyclophosphamide can be decreased when combined with Relugolix.]
[L01FX21, naxitamab, Cyclophosphamide may increase the neurotoxic activities of Naxitamab.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Cyclophosphamide can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The metabolism of Cyclophosphamide can be decreased when combined with Tepotinib.]
[N03AX10, felbamate, The metabolism of Cyclophosphamide can be increased when combined with Felbamate.]
[G04CB01, finasteride, The metabolism of Cyclophosphamide can be decreased when combined with Finasteride.]
[R03BA03, flunisolide, The metabolism of Cyclophosphamide can be increased when combined with Flunisolide.]
[R03CC15, formoterol, The metabolism of Cyclophosphamide can be decreased when combined with Formoterol.]
[L04AA50, ponesimod, The metabolism of Cyclophosphamide can be decreased when combined with Ponesimod.]
[S01LA08, bevacizumab, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Cyclophosphamide.]
[L01EK03, tivozanib, The metabolism of Tivozanib can be increased when combined with Cyclophosphamide.]
[L03AB10, peginterferon alfa-2b, The metabolism of Cyclophosphamide can be increased when combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, The metabolism of Cyclophosphamide can be decreased when combined with Cimetidine.]
[N07CA02, cinnarizine, The metabolism of Cyclophosphamide can be decreased when combined with Cinnarizine.]
[L01XX73, sotorasib, The serum concentration of Cyclophosphamide can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Cyclophosphamide can be decreased when combined with Infigratinib.]
[S03AA07, ciprofloxacin, The metabolism of Cyclophosphamide can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The metabolism of Cyclophosphamide can be decreased when combined with Cisplatin.]
[N06AB04, citalopram, The metabolism of Cyclophosphamide can be decreased when combined with Citalopram.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Pegcetacoplan.]
[H01AC07, somapacitan, The metabolism of Cyclophosphamide can be decreased when combined with Somapacitan.]
[C03DA05, finerenone, The metabolism of Finerenone can be increased when combined with Cyclophosphamide.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Belumosudil.]
[P01CA03, fexinidazole, The metabolism of Cyclophosphamide can be decreased when combined with Fexinidazole.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Anifrolumab.]
[L01XX74, belzutifan, The serum concentration of Cyclophosphamide can be decreased when it is combined with Belzutifan.]
[L01EB10, mobocertinib, The serum concentration of Cyclophosphamide can be decreased when it is combined with Mobocertinib.]
[L04AA59, avacopan, The metabolism of Cyclophosphamide can be decreased when combined with Avacopan.]
[A10BB12, glimepiride, The metabolism of Cyclophosphamide can be decreased when combined with Glimepiride.]
[A10BB08, gliquidone, The metabolism of Gliquidone can be decreased when combined with Cyclophosphamide.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Cyclophosphamide.]
[N06AX25, St. John's wort extract, The metabolism of Cyclophosphamide can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Cyclophosphamide can be increased when it is combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Ropeginterferon alfa-2b.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Cyclophosphamide.]
[J04BA01, clofazimine, The metabolism of Cyclophosphamide can be decreased when combined with Clofazimine.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Cyclophosphamide.]
[C10AB01, clofibrate, The metabolism of Cyclophosphamide can be increased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Cyclophosphamide can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Cyclophosphamide can be increased when it is combined with Pacritinib.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be increased when combined with Cyclophosphamide.]
[N03AE01, clonazepam, The metabolism of Clonazepam can be increased when combined with Cyclophosphamide.]
[S01EA04, clonidine, The metabolism of Clonidine can be increased when combined with Cyclophosphamide.]
[C01EB24, mavacamten, The serum concentration of Cyclophosphamide can be decreased when it is combined with Mavacamten.]
[A02BC08, vonoprazan, The metabolism of Cyclophosphamide can be decreased when combined with Vonoprazan.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Deucravacitinib.]
[N05AH06, clothiapine, Cyclophosphamide may increase the neurotoxic activities of Clothiapine.]
[H01CC04, linzagolix, The serum concentration of Cyclophosphamide can be increased when it is combined with Linzagolix.]
[N05BA21, clotiazepam, The metabolism of Cyclophosphamide can be decreased when combined with Clotiazepam.]
[A04AA01, ondansetron, The metabolism of Cyclophosphamide can be decreased when combined with Ondansetron.]
[J05AX31, lenacapavir, The metabolism of Cyclophosphamide can be decreased when combined with Lenacapavir.]
[N05AH02, clozapine, The risk or severity of neutropenia can be increased when Cyclophosphamide is combined with Clozapine.]
[H01AC08, somatrogon, The metabolism of Cyclophosphamide can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Cocaine.]
[L04AC21, bimekizumab, The metabolism of Cyclophosphamide can be increased when combined with Bimekizumab.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Leflunomide.]
[A10BX03, nateglinide, The metabolism of Cyclophosphamide can be decreased when combined with Nateglinide.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Nelarabine.]
[J01FA15, telithromycin, The metabolism of Cyclophosphamide can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of bleeding can be increased when Indobufen is combined with Cyclophosphamide.]
[M01AH03, valdecoxib, The metabolism of Cyclophosphamide can be decreased when combined with Valdecoxib.]
[C01AA06, lanatoside C, Lanatoside C may decrease the cardiotoxic activities of Cyclophosphamide.]
[A03AX10, isometheptene, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Isometheptene.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be increased when combined with Cyclophosphamide.]
[M01AH04, parecoxib, The metabolism of Parecoxib can be decreased when combined with Cyclophosphamide.]
[J02AC02, itraconazole, The metabolism of Cyclophosphamide can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Cyclophosphamide.]
[N05BA10, ketazolam, The metabolism of Cyclophosphamide can be decreased when combined with Ketazolam.]
[L01EA01, imatinib, The serum concentration of Cyclophosphamide can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Cyclophosphamide can be decreased when combined with Posaconazole.]
[A02BC05, esomeprazole, The metabolism of Cyclophosphamide can be decreased when combined with Esomeprazole.]
[V03AF07, rasburicase, The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Cyclophosphamide.]
[B03XA02, darbepoetin alfa, The risk or severity of pulmonary toxicity can be increased when Darbepoetin alfa is combined with Cyclophosphamide.]
[S01BA03, cortisone, The metabolism of Cyclophosphamide can be increased when combined with Cortisone.]
[R06AX13, loratadine, The metabolism of Cyclophosphamide can be decreased when combined with Loratadine.]
[C08CA11, manidipine, The metabolism of Cyclophosphamide can be decreased when combined with Manidipine.]
[H02AB15, meprednisone, The metabolism of Cyclophosphamide can be increased when combined with Meprednisone.]
[R06AD07, mequitazine, The metabolism of Cyclophosphamide can be decreased when combined with Mequitazine.]
[R06AE03, cyclizine, The metabolism of Cyclophosphamide can be decreased when combined with Cyclizine.]
[C03DA04, eplerenone, The metabolism of Cyclophosphamide can be decreased when combined with Eplerenone.]
[N05AD03, metylperon, Cyclophosphamide may increase the neurotoxic activities of Melperone.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Cyclophosphamide.]
[C03AA07, cyclopenthiazide, The risk or severity of granulocytopenia can be increased when Cyclopenthiazide is combined with Cyclophosphamide.]
[J01FA03, midecamycin, The metabolism of Cyclophosphamide can be decreased when combined with Midecamycin.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Antilymphocyte immunoglobulin (horse).]
[S01AA13, fusidic acid, The metabolism of Cyclophosphamide can be decreased when combined with Fusidic acid.]
[S02BA08, fluocinolone acetonide, The metabolism of Cyclophosphamide can be increased when combined with Fluocinolone acetonide.]
[M01AG01, mefenamic acid, The metabolism of Mefenamic acid can be decreased when combined with Cyclophosphamide.]
[J04AB01, cycloserine, Cycloserine may increase the neurotoxic activities of Cyclophosphamide.]
[S01XA18, cyclosporine, The serum concentration of Cyclosporine can be decreased when it is combined with Cyclophosphamide.]
[N06AG02, moclobemide, The metabolism of Cyclophosphamide can be decreased when combined with Moclobemide.]
[N06BA07, modafinil, The metabolism of Cyclophosphamide can be increased when combined with Modafinil.]
[C10AA07, rosuvastatin, The metabolism of Cyclophosphamide can be decreased when combined with Rosuvastatin.]
[C03XA02, conivaptan, The metabolism of Cyclophosphamide can be decreased when combined with Conivaptan.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Cytarabine.]
[G04BE09, vardenafil, The metabolism of Cyclophosphamide can be decreased when combined with Vardenafil.]
[M01AH05, etoricoxib, The metabolism of Cyclophosphamide can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Dacarbazine.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Dactinomycin.]
[G03XA01, danazol, The metabolism of Cyclophosphamide can be decreased when combined with Danazol.]
[J04BA02, dapsone, The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Cyclophosphamide.]
[L01DB02, daunorubicin, The metabolism of Cyclophosphamide can be decreased when combined with Daunorubicin.]
[A04AD11, nabilone, The metabolism of Cyclophosphamide can be decreased when combined with Nabilone.]
[M01AX01, nabumetone, The metabolism of Cyclophosphamide can be decreased when combined with Nabumetone.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Cyclophosphamide.]
[N06AX06, nefazodone, The metabolism of Cyclophosphamide can be decreased when combined with Nefazodone.]
[L02BB02, nilutamide, The metabolism of Cyclophosphamide can be decreased when combined with Nilutamide.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be increased when combined with Cyclophosphamide.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Fondaparinux is combined with Cyclophosphamide.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cyclophosphamide.]
[N06AB10, escitalopram, The metabolism of Escitalopram can be decreased when combined with Cyclophosphamide.]
[N06AA01, desipramine, The metabolism of Cyclophosphamide can be decreased when combined with Desipramine.]
[C01AA07, deslanoside, Deslanoside may decrease the cardiotoxic activities of Cyclophosphamide.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Desoximetasone.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Cyclophosphamide.]
[N03AF02, oxcarbazepine, The metabolism of Cyclophosphamide can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Cyclophosphamide can be increased when combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Cyclophosphamide can be decreased when combined with Oxybutynin.]
[L04AB04, adalimumab, The metabolism of Cyclophosphamide can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Cyclophosphamide can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, The metabolism of Cyclophosphamide can be decreased when combined with Amphetamine.]
[R05DA09, dextromethorphan, The metabolism of Cyclophosphamide can be decreased when combined with Dextromethorphan.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be increased when combined with Cyclophosphamide.]
[N06AB05, paroxetine, The metabolism of Cyclophosphamide can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Cyclophosphamide can be decreased when combined with Clopidogrel.]
[N05BA01, diazepam, The metabolism of Cyclophosphamide can be decreased when combined with Diazepam.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Phenol.]
[N06AA08, dibenzepin, Cyclophosphamide may increase the neurotoxic activities of Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Cinchocaine.]
[S01BC03, diclofenac, The metabolism of Cyclophosphamide can be decreased when combined with Diclofenac.]
[J01CF01, dicloxacillin, The metabolism of Cyclophosphamide can be increased when combined with Dicloxacillin.]
[J05AF02, didanosine, Cyclophosphamide may increase the neurotoxic activities of Didanosine.]
[A10BG03, pioglitazone, The metabolism of Pioglitazone can be increased when combined with Cyclophosphamide.]
[N05AD05, pipamperone, Cyclophosphamide may increase the neurotoxic activities of Pipamperone.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be increased when combined with Cyclophosphamide.]
[L01EB02, erlotinib, The serum concentration of Erlotinib can be decreased when it is combined with Cyclophosphamide.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Pirarubicin.]
[L03AA13, pegfilgrastim, The risk or severity of pulmonary toxicity can be increased when Pegfilgrastim is combined with Cyclophosphamide.]
[L02AA01, diethylstilbestrol, The metabolism of Cyclophosphamide can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Cyclophosphamide can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The metabolism of Cyclophosphamide can be increased when combined with Difluocortolone.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be increased when combined with Cyclophosphamide.]
[C01AA05, digoxin, Digoxin may decrease the cardiotoxic activities of Cyclophosphamide.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cyclophosphamide.]
[C04AE04, dihydroergocristine, The metabolism of Cyclophosphamide can be decreased when combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be increased when combined with Cyclophosphamide.]
[N02AA03, hydromorphone, The metabolism of Cyclophosphamide can be decreased when combined with Hydromorphone.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Cyclophosphamide.]
[J05AE08, atazanavir, The serum concentration of the active metabolites of Cyclophosphamide can be increased when Cyclophosphamide is used in combination with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Treprostinil can be increased when combined with Cyclophosphamide.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Cyclophosphamide can be decreased when combined with Diltiazem.]
[M02AX03, dimethyl sulfoxide, The metabolism of Cyclophosphamide can be decreased when combined with Dimethyl sulfoxide.]
[C05CA03, diosmin, The metabolism of Cyclophosphamide can be decreased when combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Diphenhydramine.]
[N05CD10, quazepam, The metabolism of Cyclophosphamide can be decreased when combined with Quazepam.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Dipyridamole is combined with Cyclophosphamide.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cyclophosphamide.]
[N06AA23, quinupramine, Cyclophosphamide may increase the neurotoxic activities of Quinupramine.]
[A03FA02, cisapride, The metabolism of Cyclophosphamide can be decreased when combined with Cisapride.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be increased when combined with Cyclophosphamide.]
[N05AL04, remoxipride, Remoxipride may increase the neurotoxic activities of Cyclophosphamide.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Natalizumab.]
[P03AA04, disulfiram, The metabolism of Cyclophosphamide can be decreased when combined with Disulfiram.]
[S02AA12, rifamycin SV, The metabolism of Cyclophosphamide can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Cyclophosphamide can be increased when combined with Rifapentine.]
[N05AX08, risperidone, The metabolism of Cyclophosphamide can be decreased when combined with Risperidone.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Cyclophosphamide.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Ropivacaine.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be increased when combined with Cyclophosphamide.]
[A04AD12, aprepitant, The metabolism of Cyclophosphamide can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be increased when combined with Cyclophosphamide.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be increased when combined with Cyclophosphamide.]
[J05AE07, fosamprenavir, The serum concentration of the active metabolites of Cyclophosphamide can be increased when Cyclophosphamide is used in combination with Fosamprenavir.]
[G04BE08, tadalafil, The metabolism of Cyclophosphamide can be decreased when combined with Tadalafil.]
[S01BC05, ketorolac, The metabolism of Ketorolac can be increased when combined with Cyclophosphamide.]
[C02KX02, ambrisentan, The metabolism of Cyclophosphamide can be decreased when combined with Ambrisentan.]
[C01EB18, ranolazine, The metabolism of Ranolazine can be increased when combined with Cyclophosphamide.]
[R03AC12, salmeterol, The metabolism of Cyclophosphamide can be decreased when combined with Salmeterol.]
[A03FA03, domperidone, The metabolism of Cyclophosphamide can be decreased when combined with Domperidone.]
[N06AA16, dothiepin, The metabolism of Dosulepin can be decreased when combined with Cyclophosphamide.]
[N06AA12, doxepin, The metabolism of Doxepin can be decreased when combined with Cyclophosphamide.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be increased when combined with Cyclophosphamide.]
[N06AB06, sertraline, The metabolism of Cyclophosphamide can be decreased when combined with Sertraline.]
[N01AB08, sevoflurane, The metabolism of Cyclophosphamide can be decreased when combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the neurotoxic activities of Cyclophosphamide.]
[C10AA01, simvastatin, The metabolism of Cyclophosphamide can be decreased when combined with Simvastatin.]
[N05AL02, sultopride, Cyclophosphamide may increase the neurotoxic activities of Sultopride.]
[H01AA01, corticotropin, The metabolism of Cyclophosphamide can be increased when combined with Corticotropin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Temozolomide.]
[M01AC02, tenoxicam, The metabolism of Cyclophosphamide can be decreased when combined with Tenoxicam.]
[D01BA02, terbinafine, The metabolism of Cyclophosphamide can be increased when combined with Terbinafine.]
[N05AB05, thiopropazate, Cyclophosphamide may increase the neurotoxic activities of Thiopropazate.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be increased when combined with Cyclophosphamide.]
[N03AX11, topiramate, The metabolism of Cyclophosphamide can be increased when combined with Topiramate.]
[C03CA04, torsemide, The metabolism of Cyclophosphamide can be decreased when combined with Torasemide.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Cyclophosphamide.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Trilostane.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Cyclophosphamide.]
[N05AL06, veralipride, Cyclophosphamide may increase the neurotoxic activities of Veralipride.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be increased when combined with Cyclophosphamide.]
[S01GX10, epinastine, The metabolism of Cyclophosphamide can be decreased when combined with Epinastine.]
[C08CA12, mepirodipine, The metabolism of Cyclophosphamide can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Cyclophosphamide can be decreased when combined with Epinephrine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Cyclophosphamide.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be increased when combined with Cyclophosphamide.]
[N03AX15, zonisamide, The metabolism of Cyclophosphamide can be decreased when combined with Zonisamide.]
[N05CF01, zopiclone, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Zopiclone.]
[N05AX11, zotepine, Cyclophosphamide may increase the neurotoxic activities of Zotepine.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Cyclophosphamide.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Carboplatin.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Iloprost is combined with Cyclophosphamide.]
[C01BG01, moricizine, Cyclophosphamide may increase the neurotoxic activities of Moricizine.]
[N02CA02, ergotamine, The metabolism of Cyclophosphamide can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The metabolism of Cyclophosphamide can be decreased when combined with Erythromycin.]
[A02BC02, pantoprazole, The metabolism of Cyclophosphamide can be decreased when combined with Pantoprazole.]
[G03CA03, estradiol, The metabolism of Cyclophosphamide can be decreased when combined with Estradiol.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Estramustine.]
[J04AK02, ethambutol, The metabolism of Cyclophosphamide can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The metabolism of Cyclophosphamide can be increased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Cyclophosphamide can be increased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Cyclophosphamide can be decreased when combined with Fluvastatin.]
[L02AA03, ethinyl estradiol, The metabolism of Cyclophosphamide can be decreased when combined with Ethinylestradiol.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Meloxicam.]
[S01XA06, ethylmorphine, The metabolism of Cyclophosphamide can be decreased when combined with Ethylmorphine.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Etidocaine.]
[L01CB01, etoposide, The metabolism of Etoposide can be increased when combined with Cyclophosphamide.]
[N05AE03, sertindole, Cyclophosphamide may increase the neurotoxic activities of Sertindole.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Cyclophosphamide.]
[R06AX11, astemizole, The metabolism of Astemizole can be increased when combined with Cyclophosphamide.]
[R06AX12, terfenadine, The metabolism of Cyclophosphamide can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The metabolism of Cyclophosphamide can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Cyclophosphamide can be decreased when combined with Fluvoxamine.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Cyclophosphamide.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Dextran is combined with Cyclophosphamide.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cyclophosphamide.]
[P02CA03, albendazole, The metabolism of Cyclophosphamide can be decreased when combined with Albendazole.]
[C08CA02, felodipine, The metabolism of Cyclophosphamide can be decreased when combined with Felodipine.]
[N03AX26, fenfluramine, The metabolism of Cyclophosphamide can be decreased when combined with Fenfluramine.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Cyclophosphamide.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Clofarabine.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Cyclophosphamide.]
[C01BC04, flecainide, The metabolism of Cyclophosphamide can be decreased when combined with Flecainide.]
[J01CF05, floxacillin, The metabolism of Cyclophosphamide can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The metabolism of Cyclophosphamide can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Flucytosine.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Fludrocortisone.]
[N07CA03, flunarizine, The metabolism of Cyclophosphamide can be decreased when combined with Flunarizine.]
[N05CD03, flunitrazepam, The metabolism of Cyclophosphamide can be decreased when combined with Flunitrazepam.]
[D07AC08, fluocinonide, The metabolism of Cyclophosphamide can be increased when combined with Fluocinonide.]
[N06AA14, melitracen, Cyclophosphamide may increase the neurotoxic activities of Melitracen.]
[H02AB03, fluocortolone, The metabolism of Cyclophosphamide can be increased when combined with Fluocortolone.]
[V03AZ01, ethanol, The metabolism of Cyclophosphamide can be increased when combined with Ethanol.]
[L01BC09, floxuridine, The metabolism of Cyclophosphamide can be decreased when combined with Floxuridine.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Cyclophosphamide.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be increased when combined with Cyclophosphamide.]
[N06AB03, fluoxetine, The metabolism of Cyclophosphamide can be decreased when combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Cyclophosphamide.]
[N05AB02, fluphenazine, Cyclophosphamide may increase the neurotoxic activities of Fluphenazine.]
[N05CD01, flurazepam, The metabolism of Cyclophosphamide can be decreased when combined with Flurazepam.]
[S01BC04, flurbiprofen, The metabolism of Flurbiprofen can be decreased when combined with Cyclophosphamide.]
[N05AG01, fluspirilene, Cyclophosphamide may increase the neurotoxic activities of Fluspirilene.]
[L02BB01, flutamide, The metabolism of Cyclophosphamide can be decreased when combined with Flutamide.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Cyclophosphamide.]
[J05AE10, darunavir, The serum concentration of Cyclophosphamide can be increased when it is combined with Darunavir.]
[N05CF04, eszopiclone, The serum concentration of Eszopiclone can be decreased when it is combined with Cyclophosphamide.]
[N05AL05, amisulpride, Cyclophosphamide may increase the neurotoxic activities of Amisulpride.]
[M03AC02, gallamine, Cyclophosphamide may increase the neurotoxic activities of Gallamine.]
[N03AA04, barbexaclone, The metabolism of Cyclophosphamide can be increased when combined with Barbexaclone.]
[C10AB04, gemfibrozil, The metabolism of Cyclophosphamide can be decreased when combined with Gemfibrozil.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be increased when combined with Cyclophosphamide.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be increased when combined with Cyclophosphamide.]
[J05AG04, etravirine, The metabolism of Cyclophosphamide can be increased when combined with Etravirine.]
[N03AD03, methsuximide, The metabolism of Cyclophosphamide can be decreased when combined with Methsuximide.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be increased when combined with Cyclophosphamide.]
[N01AH02, alfentanil, The metabolism of Cyclophosphamide can be decreased when combined with Alfentanil.]
[L01EH01, lapatinib, The metabolism of Cyclophosphamide can be decreased when combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Cyclophosphamide can be decreased when combined with Glyburide.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Cyclophosphamide.]
[A10BB07, glipizide, The metabolism of Glipizide can be decreased when combined with Cyclophosphamide.]
[C05AE01, nitroglycerin, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Nitroglycerin.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be increased when combined with Cyclophosphamide.]
[C02CA04, doxazosin, The metabolism of Cyclophosphamide can be decreased when combined with Doxazosin.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be increased when combined with Cyclophosphamide.]
[B01AA12, fluindione, The therapeutic efficacy of Fluindione can be increased when used in combination with Cyclophosphamide.]
[D01BA01, griseofulvin, The metabolism of Cyclophosphamide can be increased when combined with Griseofulvin.]
[P01BX01, halofantrine, The metabolism of Cyclophosphamide can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Cyclophosphamide.]
[N01AB01, halothane, The metabolism of Cyclophosphamide can be decreased when combined with Halothane.]
[N05AH04, quetiapine, The metabolism of Cyclophosphamide can be decreased when combined with Quetiapine.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be increased when combined with Cyclophosphamide.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Cyclophosphamide.]
[C09CA01, losartan, The metabolism of Cyclophosphamide can be decreased when combined with Losartan.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Cyclophosphamide.]
[G03DC01, allylestrenol, The metabolism of Cyclophosphamide can be decreased when combined with Allylestrenol.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Cyclophosphamide.]
[N05CA16, hexobarbital, The metabolism of Hexobarbital can be decreased when combined with Cyclophosphamide.]
[J05AG01, nevirapine, The metabolism of Cyclophosphamide can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Cyclophosphamide can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of bleeding can be increased when Nimesulide is combined with Cyclophosphamide.]
[C02DB02, hydralazine, The metabolism of Cyclophosphamide can be decreased when combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of granulocytopenia can be increased when Hydrochlorothiazide is combined with Cyclophosphamide.]
[R05DA03, hydrocodone, The metabolism of Cyclophosphamide can be decreased when combined with Hydrocodone.]
[S02BA01, hydrocortisone, The metabolism of Cyclophosphamide can be increased when combined with Hydrocortisone.]
[C03AA02, hydroflumethiazide, The risk or severity of granulocytopenia can be increased when Hydroflumethiazide is combined with Cyclophosphamide.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Hydroxychloroquine.]
[N05AX07, prothipendyl, Cyclophosphamide may increase the neurotoxic activities of Prothipendyl.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Hydroxyurea.]
[N05BB01, hydroxyzine, The metabolism of Cyclophosphamide can be decreased when combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Cyclophosphamide can be increased when combined with Rifabutin.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be increased when combined with Cyclophosphamide.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Cyclophosphamide.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Idarubicin.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be increased when combined with Cyclophosphamide.]
[N06AA02, imipramine, The metabolism of Cyclophosphamide can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be increased when combined with Cyclophosphamide.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Tixocortol.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Topotecan.]
[C03BA11, indapamide, The risk or severity of granulocytopenia can be increased when Indapamide is combined with Cyclophosphamide.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Cyclophosphamide.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Cyclophosphamide.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cyclophosphamide.]
[N06AX17, milnacipran, The metabolism of Milnacipran can be increased when combined with Cyclophosphamide.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Eculizumab.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Articaine.]
[A10BH01, sitagliptin, The metabolism of Sitagliptin can be increased when combined with Cyclophosphamide.]
[N05BA12, alprazolam, The metabolism of Cyclophosphamide can be decreased when combined with Alprazolam.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be decreased when combined with Cyclophosphamide.]
[C10AA06, cerivastatin, The metabolism of Cyclophosphamide can be increased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Anagrelide is combined with Cyclophosphamide.]
[C03BA02, quinethazone, The risk or severity of granulocytopenia can be increased when Quinethazone is combined with Cyclophosphamide.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cyclophosphamide.]
[J05AF04, stavudine, Cyclophosphamide may increase the neurotoxic activities of Stavudine.]
[N06AA13, iprindole, Cyclophosphamide may increase the neurotoxic activities of Iprindole.]
[N06AF05, iproniazid, The metabolism of Cyclophosphamide can be decreased when combined with Iproniazid.]
[N05AA07, chlorproethazine, Cyclophosphamide may increase the neurotoxic activities of Chlorproethazine.]
[P01AX06, atovaquone, The metabolism of Cyclophosphamide can be decreased when combined with Atovaquone.]
[N01AB06, isoflurane, The metabolism of Cyclophosphamide can be decreased when combined with Isoflurane.]
[J04AC01, isoniazid, The metabolism of Cyclophosphamide can be decreased when combined with Isoniazid.]
[C05AE02, isosorbide dinitrate, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Isosorbide dinitrate.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Cyclophosphamide.]
[L04AC07, tocilizumab, The metabolism of Cyclophosphamide can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Cyclophosphamide can be decreased when combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Cyclophosphamide.]
[B01AC22, prasugrel, The metabolism of Cyclophosphamide can be decreased when combined with Prasugrel.]
[J02AB02, ketoconazole, The metabolism of Cyclophosphamide can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The metabolism of Cyclophosphamide can be decreased when combined with Olanzapine.]
[M02AA10, ketoprofen, The metabolism of Cyclophosphamide can be decreased when combined with Ketoprofen.]
[V03AC03, deferasirox, The metabolism of Cyclophosphamide can be increased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Cyclophosphamide can be increased when combined with Abatacept.]
[C07AG01, labetalol, The metabolism of Labetalol can be decreased when combined with Cyclophosphamide.]
[N03AX18, lacosamide, The metabolism of Cyclophosphamide can be decreased when combined with Lacosamide.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Cyclophosphamide.]
[G03AD01, levonorgestrel, The metabolism of Cyclophosphamide can be decreased when combined with Levonorgestrel.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Lidocaine.]
[J01FF02, lincomycin, Cyclophosphamide may increase the neurotoxic activities of Lincomycin.]
[N06BA13, armodafinil, The metabolism of Cyclophosphamide can be increased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be increased when combined with Cyclophosphamide.]
[N06AA07, lofepramine, Cyclophosphamide may increase the neurotoxic activities of Lofepramine.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Lomustine.]
[A07DA03, loperamide, The metabolism of Loperamide can be increased when combined with Cyclophosphamide.]
[C10AA02, lovastatin, The metabolism of Cyclophosphamide can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, Loxapine may increase the neurotoxic activities of Cyclophosphamide.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be increased when combined with Cyclophosphamide.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be increased when combined with Cyclophosphamide.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Pralatrexate.]
[L01EA03, nilotinib, The metabolism of Cyclophosphamide can be decreased when combined with Nilotinib.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Mechlorethamine.]
[C01AA08, medigoxin, Metildigoxin may decrease the cardiotoxic activities of Cyclophosphamide.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Cyclophosphamide.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Cyclophosphamide.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Cyclophosphamide.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Melphalan.]
[N06DX01, memantine, The metabolism of Cyclophosphamide can be decreased when combined with Memantine.]
[N02AB02, meperidine, The metabolism of Cyclophosphamide can be decreased when combined with Meperidine.]
[N03AB04, mephenytoin, The metabolism of Cyclophosphamide can be decreased when combined with Mephenytoin.]
[N03AA01, mephobarbital, The metabolism of Cyclophosphamide can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Mepivacaine.]
[L02BG01, aminoglutethimide, The metabolism of Cyclophosphamide can be increased when combined with Aminoglutethimide.]
[N05AC03, mesoridazine, Cyclophosphamide may increase the neurotoxic activities of Mesoridazine.]
[N05AX13, paliperidone, The metabolism of Cyclophosphamide can be decreased when combined with Paliperidone.]
[H01CB03, lanreotide, The metabolism of Cyclophosphamide can be decreased when combined with Lanreotide.]
[N07BC02, methadone, The metabolism of Cyclophosphamide can be decreased when combined with Methadone.]
[H03BB02, methimazole, The metabolism of Cyclophosphamide can be decreased when combined with Methimazole.]
[L03AA02, filgrastim, The risk or severity of pulmonary toxicity can be increased when Filgrastim is combined with Cyclophosphamide.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Pemetrexed.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be increased when combined with Cyclophosphamide.]
[N05AA02, methotrimeprazine, Cyclophosphamide may increase the neurotoxic activities of Methotrimeprazine.]
[D05BA02, methoxsalen, The metabolism of Cyclophosphamide can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The metabolism of Cyclophosphamide can be decreased when combined with Methoxyflurane.]
[C03AA08, methyclothiazide, The risk or severity of granulocytopenia can be increased when Methyclothiazide is combined with Cyclophosphamide.]
[V04CG05, methylene blue, The metabolism of Cyclophosphamide can be decreased when combined with Methylene blue.]
[G02AB01, methylergonovine, The metabolism of Cyclophosphamide can be decreased when combined with Methylergometrine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be increased when combined with Cyclophosphamide.]
[H02AB04, methylprednisolone, The metabolism of Cyclophosphamide can be increased when combined with Methylprednisolone.]
[N03AF03, rufinamide, The metabolism of Cyclophosphamide can be increased when combined with Rufinamide.]
[G03EK01, methyltestosterone, The metabolism of Cyclophosphamide can be decreased when combined with Methyltestosterone.]
[N02CA04, methysergide, The metabolism of Cyclophosphamide can be decreased when combined with Methysergide.]
[A03FA01, metoclopramide, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Metoclopramide.]
[C03BA08, metolazone, The risk or severity of granulocytopenia can be increased when Metolazone is combined with Cyclophosphamide.]
[P01AB01, metronidazole, The metabolism of Cyclophosphamide can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, The metabolism of Cyclophosphamide can be increased when combined with Metyrapone.]
[C01BB02, mexiletine, The metabolism of Cyclophosphamide can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The metabolism of Cyclophosphamide can be decreased when combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Cyclophosphamide can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be increased when combined with Cyclophosphamide.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Cyclophosphamide.]
[N05CD08, midazolam, The metabolism of Cyclophosphamide can be decreased when combined with Midazolam.]
[L03AA09, sargramostim, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Sargramostim.]
[G03XB01, mifepristone, The serum concentration of Cyclophosphamide can be increased when it is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Cyclophosphamide.]
[C09CA03, valsartan, The metabolism of Cyclophosphamide can be decreased when combined with Valsartan.]
[J01FA11, miocamycin, The metabolism of Cyclophosphamide can be decreased when combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Cyclophosphamide can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Mitoxantrone.]
[L03AA03, molgramostim, The risk or severity of pulmonary toxicity can be increased when Molgramostim is combined with Cyclophosphamide.]
[L03AA10, lenograstim, The risk or severity of pulmonary toxicity can be increased when Lenograstim is combined with Cyclophosphamide.]
[N05AE02, molindone, Cyclophosphamide may increase the neurotoxic activities of Molindone.]
[L03AC01, aldesleukin, The metabolism of Cyclophosphamide can be decreased when combined with Aldesleukin.]
[C01BD01, amiodarone, The risk or severity of pulmonary toxicity can be increased when Cyclophosphamide is combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Cyclophosphamide can be decreased when combined with Amitriptyline.]
[N02AA01, morphine, The metabolism of Morphine can be increased when combined with Cyclophosphamide.]
[L04AB05, certolizumab pegol, The metabolism of Cyclophosphamide can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Cyclophosphamide can be decreased when combined with Eltrombopag.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Ofatumumab.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be increased when combined with Cyclophosphamide.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Mycophenolic acid.]
[N05CA02, amobarbital, The metabolism of Cyclophosphamide can be increased when combined with Amobarbital.]
[P01BA06, amodiaquine, The metabolism of Cyclophosphamide can be decreased when combined with Amodiaquine.]
[G03XC01, raloxifene, The metabolism of Cyclophosphamide can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, Cyclophosphamide may increase the neurotoxic activities of Amoxapine.]
[N03AB05, fosphenytoin, The metabolism of Cyclophosphamide can be increased when combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cyclophosphamide.]
[J01CF06, nafcillin, The metabolism of Cyclophosphamide can be increased when combined with Nafcillin.]
[V03AB15, naloxone, The metabolism of Cyclophosphamide can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Cyclophosphamide can be increased when combined with Anakinra.]
[N06BA01, amphetamine, The metabolism of Cyclophosphamide can be decreased when combined with Amphetamine.]
[M02AA12, naproxen, The metabolism of Naproxen can be increased when combined with Cyclophosphamide.]
[A10BG01, troglitazone, The metabolism of Cyclophosphamide can be increased when combined with Troglitazone.]
[N06AX21, duloxetine, The metabolism of Cyclophosphamide can be decreased when combined with Duloxetine.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of pulmonary toxicity can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cyclophosphamide.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be increased when combined with Cyclophosphamide.]
[L02BG04, letrozole, The metabolism of Cyclophosphamide can be decreased when combined with Letrozole.]
[S03AA01, neomycin, Cyclophosphamide may increase the neurotoxic activities of Neomycin.]
[A10BX02, repaglinide, The metabolism of Repaglinide can be increased when combined with Cyclophosphamide.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Cyclophosphamide.]
[N05AX14, iloperidone, The metabolism of Cyclophosphamide can be decreased when combined with Iloperidone.]
[N06AX23, desvenlafaxine, The metabolism of Cyclophosphamide can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, The metabolism of Cyclophosphamide can be decreased when combined with Telmisartan.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Cyclophosphamide.]
[C10AD02, niacin, The metabolism of Cyclophosphamide can be decreased when combined with Niacin.]
[C08CA04, nicardipine, The metabolism of Cyclophosphamide can be decreased when combined with Nicardipine.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Cyclophosphamide.]
[N07BA01, nicotine, The metabolism of Cyclophosphamide can be decreased when combined with Nicotine.]
[C08CA05, nifedipine, The metabolism of Cyclophosphamide can be decreased when combined with Nifedipine.]
[V03AB22, amyl nitrite, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Amyl Nitrite.]
[C08CA07, nisoldipine, The metabolism of Cyclophosphamide can be decreased when combined with Nisoldipine.]
[C08CA08, nitrendipine, The metabolism of Cyclophosphamide can be decreased when combined with Nitrendipine.]
[R07AX01, nitric oxide, The risk or severity of methemoglobinemia can be increased when Nitric Oxide is combined with Cyclophosphamide.]
[J01XE01, nitrofurantoin, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Nitrofurantoin.]
[N05CF03, zaleplon, The metabolism of Cyclophosphamide can be decreased when combined with Zaleplon.]
[C02DD01, nitroprusside, The risk or severity of methemoglobinemia can be increased when Nitroprusside is combined with Cyclophosphamide.]
[N01AX13, nitrous oxide, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Nitrous oxide.]
[G03DC02, norethindrone, The metabolism of Cyclophosphamide can be decreased when combined with Norethisterone.]
[G03AC07, norgestrienone, The metabolism of Norgestrienone can be increased when combined with Cyclophosphamide.]
[C02KX01, bosentan, The metabolism of Cyclophosphamide can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be increased when combined with Cyclophosphamide.]
[R05DA07, noscapine, The metabolism of Cyclophosphamide can be decreased when combined with Noscapine.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Cyclophosphamide.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Cyclophosphamide.]
[H01CB02, octreotide, The serum concentration of Cyclophosphamide can be increased when it is combined with Octreotide.]
[J01FA05, oleandomycin, The metabolism of Cyclophosphamide can be decreased when combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Cyclophosphamide can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Cyclophosphamide can be increased when combined with Omeprazole.]
[N06AA05, opipramol, Cyclophosphamide may increase the neurotoxic activities of Opipramol.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Cyclophosphamide.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Cyclophosphamide.]
[C01AC01, ouabain, Ouabain may decrease the cardiotoxic activities of Cyclophosphamide.]
[A14AA08, oxandrolone, The metabolism of Cyclophosphamide can be decreased when combined with Oxandrolone.]
[N02AA05, oxycodone, The metabolism of Cyclophosphamide can be decreased when combined with Oxycodone.]
[N05AE01, oxypertine, Cyclophosphamide may increase the neurotoxic activities of Oxypertine.]
[J04AA01, aminosalicylic acid, The risk or severity of methemoglobinemia can be increased when Aminosalicylic acid is combined with Cyclophosphamide.]
[N05AH05, asenapine, Cyclophosphamide may increase the neurotoxic activities of Asenapine.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Cyclophosphamide.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be increased when combined with Cyclophosphamide.]
[H02AB05, paramethasone, The metabolism of Cyclophosphamide can be increased when combined with Paramethasone.]
[N05AG03, penfluridol, Cyclophosphamide may increase the neurotoxic activities of Penfluridol.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Penicillamine.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclophosphamide.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclophosphamide.]
[N05CA01, pentobarbital, The metabolism of Cyclophosphamide can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Pentostatin may increase the cardiotoxic activities of Cyclophosphamide.]
[C04AD03, pentoxifylline, The risk or severity of bleeding can be increased when Pentoxifylline is combined with Cyclophosphamide.]
[N05AB10, perazine, Cyclophosphamide may increase the neurotoxic activities of Perazine.]
[C08EX02, perhexiline, The metabolism of Cyclophosphamide can be decreased when combined with Perhexiline.]
[B02BX04, romiplostim, The risk or severity of pulmonary toxicity can be increased when Romiplostim is combined with Cyclophosphamide.]
[N05AB03, perphenazine, Cyclophosphamide may increase the neurotoxic activities of Perphenazine.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Cyclophosphamide.]
[N02BE03, phenacetin, The metabolism of Cyclophosphamide can be decreased when combined with Phenacetin.]
[G04BX06, phenazopyridine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Phenazopyridine.]
[B01AA02, phenindione, The therapeutic efficacy of Phenindione can be increased when used in combination with Cyclophosphamide.]
[N03AA02, phenobarbital, The metabolism of Cyclophosphamide can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Cyclophosphamide.]
[M02AA01, phenylbutazone, The metabolism of Cyclophosphamide can be increased when combined with Phenylbutazone.]
[A02BC06, dexlansoprazole, The metabolism of Cyclophosphamide can be decreased when combined with Dexlansoprazole.]
[N03AB02, phenytoin, The metabolism of Cyclophosphamide can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Cyclophosphamide can be increased when combined with Golimumab.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be increased when combined with Cyclophosphamide.]
[C08CX01, mibefradil, The metabolism of Cyclophosphamide can be decreased when combined with Mibefradil.]
[S01EB01, pilocarpine, The metabolism of Cyclophosphamide can be decreased when combined with Pilocarpine.]
[N05AG02, pimozide, The metabolism of Pimozide can be increased when combined with Cyclophosphamide.]
[C10AA05, atorvastatin, The metabolism of Cyclophosphamide can be decreased when combined with Atorvastatin.]
[J05AE01, saquinavir, The serum concentration of the active metabolites of Cyclophosphamide can be increased when Cyclophosphamide is used in combination with Saquinavir.]
[N05AC04, pipothiazine, Cyclophosphamide may increase the neurotoxic activities of Pipotiazine.]
[S01BC06, piroxicam, The metabolism of Piroxicam can be increased when combined with Cyclophosphamide.]
[J05AG02, delavirdine, The metabolism of Cyclophosphamide can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Cyclophosphamide can be decreased when combined with Irbesartan.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Cyclophosphamide.]
[D05AX05, tazarotene, The metabolism of Tazarotene can be increased when combined with Cyclophosphamide.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Cyclophosphamide.]
[A10BG02, rosiglitazone, The metabolism of Rosiglitazone can be increased when combined with Cyclophosphamide.]
[L02BG03, anastrozole, The risk or severity of cardiotoxicity can be increased when Cyclophosphamide is combined with Anastrozole.]
[A03AE01, alosetron, The metabolism of Alosetron can be decreased when combined with Cyclophosphamide.]
[L04AC08, canakinumab, The metabolism of Cyclophosphamide can be increased when combined with Canakinumab.]
[S03AA03, polymyxin B, Cyclophosphamide may increase the neurotoxic activities of Polymyxin B.]
[C03AA05, polythiazide, The risk or severity of granulocytopenia can be increased when Polythiazide is combined with Cyclophosphamide.]
[J05AE03, ritonavir, The serum concentration of the active metabolites of Cyclophosphamide can be increased when Cyclophosphamide is used in combination with Ritonavir.]
[A10BH03, saxagliptin, The metabolism of Cyclophosphamide can be decreased when combined with Saxagliptin.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be increased when combined with Cyclophosphamide.]
[P02BA01, praziquantel, The metabolism of Cyclophosphamide can be decreased when combined with Praziquantel.]
[S03BA02, prednisolone, The metabolism of Cyclophosphamide can be increased when combined with Prednisolone.]
[H02AB07, prednisone, The metabolism of Cyclophosphamide can be increased when combined with Prednisone.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Cyclophosphamide can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Cyclophosphamide can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Cyclophosphamide can be increased when combined with Probenecid.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Procarbazine.]
[C10AB05, fenofibrate, The metabolism of Cyclophosphamide can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, Prochlorperazine may increase the neurotoxic activities of Cyclophosphamide.]
[G03DA04, progesterone, The metabolism of Cyclophosphamide can be decreased when combined with Progesterone.]
[N05AA03, promazine, The metabolism of Cyclophosphamide can be decreased when combined with Promazine.]
[R06AD02, promethazine, The metabolism of Cyclophosphamide can be decreased when combined with Promethazine.]
[N05AC01, periciazine, Cyclophosphamide may increase the neurotoxic activities of Periciazine.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be increased when combined with Cyclophosphamide.]
[N01AX10, propofol, The metabolism of Cyclophosphamide can be decreased when combined with Propofol.]
[N02AC04, propoxyphene, The metabolism of Cyclophosphamide can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, The metabolism of Cyclophosphamide can be decreased when combined with Propranolol.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Propylthiouracil.]
[C01AB01, proscillaridin, Proscillaridin may decrease the cardiotoxic activities of Cyclophosphamide.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Cyclophosphamide.]
[R03DC03, montelukast, The metabolism of Cyclophosphamide can be decreased when combined with Montelukast.]
[N06AA11, protriptyline, Protriptyline may increase the neurotoxic activities of Cyclophosphamide.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be increased when combined with Cyclophosphamide.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Cyclophosphamide.]
[P01BD01, pyrimethamine, The metabolism of Cyclophosphamide can be decreased when combined with Pyrimethamine.]
[P01AX05, quinacrine, The metabolism of Cyclophosphamide can be decreased when combined with Quinacrine.]
[C01BA01, quinidine, The metabolism of Quinidine can be increased when combined with Cyclophosphamide.]
[P01BC01, quinine, The metabolism of Cyclophosphamide can be increased when combined with Quinine.]
[C02AA02, reserpine, The metabolism of Cyclophosphamide can be increased when combined with Reserpine.]
[J04AB02, rifampin, The metabolism of Cyclophosphamide can be increased when combined with Rifampicin.]
[J01FA06, roxithromycin, The metabolism of Cyclophosphamide can be decreased when combined with Roxithromycin.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The metabolism of Salicylic acid can be decreased when combined with Cyclophosphamide.]
[N05CA06, secobarbital, The metabolism of Cyclophosphamide can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The metabolism of Cyclophosphamide can be decreased when combined with Selegiline.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Cyclophosphamide.]
[H01CB01, somatostatin, The metabolism of Cyclophosphamide can be decreased when combined with Somatostatin.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be increased when combined with Cyclophosphamide.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cyclophosphamide.]
[C03DA01, spironolactone, The metabolism of Cyclophosphamide can be decreased when combined with Spironolactone.]
[N03AG01, valproic acid, The metabolism of Cyclophosphamide can be decreased when combined with Valproic acid.]
[D07AB02, hydrocortisone butyrate, The metabolism of Cyclophosphamide can be increased when combined with Hydrocortisone butyrate.]
[L01CD03, paclitaxel poliglumex, The risk or severity of cardiotoxicity can be increased when Cyclophosphamide is combined with Paclitaxel poliglumex.]
[C01DA14, isosorbide mononitrate, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Isosorbide mononitrate.]
[H02CA04, levoketoconazole, The metabolism of Cyclophosphamide can be decreased when combined with Levoketoconazole.]
